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ABSTRACT 
 
ANDREW JAY EDMONDS: The effects of highly active antiretroviral therapy on 
survival and CD4 cell percentage in HIV-infected children in Kinshasa, Democratic 
Republic of Congo 
(Under the direction of Frieda Behets) 
 
 
 
In HIV-infected children, the effects of highly active antiretroviral therapy 
(HAART) on survival and CD4 responses are understood incompletely. As most pediatric 
HIV infections occur in lower-income countries, our objective was to provide the first 
estimates of these effects among children in a resource-deprived setting. 
Observational data from HAART-naïve children enrolled into an HIV care and 
treatment program in Kinshasa, Democratic Republic of Congo between December 2004 
and May 2010 were analyzed. Marginal structural models were used to quantify the 
effects of HAART on survival and CD4 percentage while accounting for time-dependent 
confounders affected by prior exposure to HAART. 
At the start of follow-up, the median age of the 790 children was 5.9 years; 528 
(67%) had advanced or severe immunodeficiency and 405 (51%) were in HIV clinical 
stage 3 or 4. The children were observed for a median of 31 months and contributed 
2,090 person-years. Eighty children (10%) died, 619 (78%) initiated HAART, six (1%) 
transferred care to another facility, and 76 (10%) were lost to follow-up. The mortality 
rate was 3.2 per 100 person-years (95% CI: 2.4, 4.2) during HAART and 6.0 (95% CI: 
4.1, 8.6) during receipt of primary HIV care only. The mortality hazard ratio comparing 
 iv 
HAART to no HAART was 0.25 (95% CI: 0.06, 0.95). Compared to no HAART, the 
estimated absolute rise in CD4 percentage was 6.8% (95% CI: 4.7%, 8.9%) after six 
months of HAART, 8.6% (95% CI: 7.0%, 10.2%) after 12 months, and 20.5% (95% CI: 
16.1%, 24.9%) after 60 months. HAART-mediated CD4 percentage gains were slowest 
but greatest among children who had a baseline CD4 percentage <15. The cumulative 
incidence of recovery to “not significant” WHO age-specific immunodeficiency was 
lower if HAART was initiated when immunodeficiency was severe rather than mild or 
advanced. 
HAART reduced the hazard of mortality and increased CD4 percentages among 
HIV-infected children in a resource-deprived setting to a similar degree as previously 
noted for children in the United States. The more gradual and protracted immunological 
recovery observed in children with lower baseline CD4 percentages supports earlier 
initiation of pediatric HAART. 
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I. 
SPECIFIC AIMS 
 
Introduction 
Human Immunodeficiency Virus (HIV), the cause of Acquired Immune 
Deficiency Syndrome (AIDS), is a major source of global morbidity and mortality. As 
the virus damages cell-mediated immunity by infecting and destroying CD4+ T 
lymphocytes (i.e., CD4 cells), the CD4 cell level is an essential immunological marker of 
HIV progression. Given that highly active antiretroviral therapy (HAART) effectively 
inhibits various phases of HIV propagation, it logically follows that HAART would 
improve both immunological and clinical outcomes, including survival. 
These beneficial impacts of HAART have been demonstrated in a variety of 
experimental and observational studies. However, despite such evidence, multiple 
knowledge gaps remain. After HAART was first shown to delay AIDS and improve 
survival, additional randomized trials comparing HAART to less potent antiretroviral 
therapy (ART) were precluded due to ethical reasons. This limited future investigations 
to quantify the effects of HAART on progression to non-experimental data, which are 
susceptible to biases including confounding by indication. Although prior observational 
studies are of immeasurable value and have greatly influenced patient care, few have 
utilized the epidemiological methods necessary to isolate the causal effects of HAART 
given the complex, time-dependent relationships between exposure, outcomes, and other 
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factors. The studies that have used those methods have generally examined adult cohorts 
in the United States. In fact, no such studies have focused on children in resource-
deprived, sub-Saharan African settings, where the HIV pandemic is most widespread. 
While the simple lack of methodologically adequate observational studies on the 
clinical progression, survival, and immunological effects of HAART in children justifies 
further investigation in this arena, increased rollout of antiretroviral drugs in resource-
deprived settings has revealed new research priorities as well as highlighted opportunities 
for novel scientific contribution. Care and treatment programs in the developing world 
operate in vastly different environments than those of more resource-privileged 
initiatives, and face specific challenges including a high prevalence of undernutrition, 
patients who are sicker upon presentation to care, fewer drug options, and decreased 
laboratory capacity to inform decision making. Although it can be argued that the effects 
of HAART in children are not definitively known in any context, there is even less 
evidence on how HAART affects clinical and immunological progression in resource-
deprived settings, and questions remain about how outcomes may be impacted by 
immunological status at time of HAART initiation. 
This research was motivated by the opportunity to expand the breadth of 
understanding on pediatric HAART along with the possibility of informing policy and 
patient care as, for example, the debate on when to initiate HAART is ongoing. Using 
observational data from 790 children participating in a comprehensive HIV care and 
treatment program in Kinshasa, Democratic Republic Congo (DRC), along with 
appropriate epidemiological methods such as marginal structural models estimated by 
inverse probability weighted regression, the following aims were addressed: 
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Specific Aim 1 
 
To estimate the causal effect of HAART on survival. 
Hypothesis: Relative to non-initiation of HAART, HAART initiation will decrease the 
hazard of death. 
 
Specific Aim 2 
 
To estimate the causal effect of HAART on mean change in CD4 percentage at each 
six month time point up to 60 months following the start of HAART, both overall 
and by category of baseline CD4 percentage (<15%, 15%–24%, ≥ 25%). 
Hypotheses: Relative to non-initiation of HAART, HAART initiation will increase the 
mean CD4 percentage at each time point. Higher CD4 percentages at baseline will be 
associated with reduced increases in CD4 percentage at all time points. 
 
Specific Aim 3 
 
To determine whether the degree of immunodeficiency at HAART initiation is 
associated with recovery to “not significant” WHO age-specific immunodeficiency. 
Hypotheses: Children with greater immunodeficiency at time of HAART initiation will 
be less likely to recover immunologically. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II. 
BACKGROUND AND SIGNIFICANCE 
 
Global Epidemiology of HIV 
HIV, the virus that causes AIDS, is a significant source of morbidity and 
mortality worldwide. In 2009, according to the Joint United Nations Programme on 
HIV/AIDS (UNAIDS), there were approximately 33.3 million people living with the 
virus, 2.6 million new HIV infections, and 1.8 million deaths due to AIDS.1 Spread 
primarily through sexual contact and injection drug use, HIV does not have a uniform 
global distribution – in 2009, it was estimated that 68% of people living with the virus 
were in sub-Saharan Africa, where 69% of new infections and 72% of AIDS-related 
deaths occurred.1 In less than 30 years, HIV has caused the deaths of 25 million 
individuals around the world.2 
Children bear a substantial portion of the global HIV burden. There were 
about 2.5 million children younger than 15 years of age living with HIV in 2009, with 
370,000 new HIV infections and 260,000 deaths due to AIDS.1 Paralleling the general 
pandemic, sub-Saharan Africa is the epicenter of pediatric HIV – in 2007, more than 90% 
of pediatric AIDS-related deaths were in that region,2 where in 2009, 92% of children 
with HIV lived. Virtually all children living with HIV were infected via vertical 
transmission either during breastfeeding, birth, or pregnancy.1  
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Table 1. Individuals living with HIV, new HIV infections, and AIDS-related deaths, 
2009. 
 Global total (in millions) % in sub-Saharan Africa
All ages <15 years All ages <15 years 
Individuals living with HIV 33.3 2.5 68 92 
New HIV infections 2.6 0.37 69 no data 
AIDS-related deaths 1.8 0.26 72 no data 
 
Data source: Global report: UNAIDS report on the global AIDS epidemic 2010.1  
 
HIV: Clinical, Survival, and Immunological Impacts 
HIV is deadly due to its deleterious effects on the immune system. The virus 
infects cells expressing the CD4 glycoprotein,3,4 including macrophages,5 dendritic cells,6 
and CD4 cells.7 During the course of HIV infection, opportunistic diseases increase over 
time8,9 as these cells, essential for cell-mediated immunity,10 are destroyed by induced 
apoptosis,11 targeting by cytotoxic CD8+ T lymphocytes,12 and direct viral killing.13 The 
most widely utilized immunological marker of HIV progression is the CD4 count;14-17 in 
children, CD4 percentage, regarded as a more stable metric, is typically used.18 There is 
perhaps no clearer way to express the importance of CD4 cells and the immunological 
effects of the virus than by examining the 2008 Centers for Disease Control and 
Prevention (CDC) case definition for AIDS – an HIV patient aged 13 years or more is 
considered to have AIDS if the CD4 count ever falls below 200 cells/μL, if the 
percentage of total lymphocytes that are CD4 cells ever falls below 14%, or if the 
individual has developed one of 27 immunodeficiency-related conditions.19 Coincident 
with the increasing risk of opportunistic diseases as HIV induces immune system failure, 
an association between low CD4 levels and mortality in adults20,21 and children22-24 has 
been demonstrated. 
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HAART can effectively inhibit HIV. The compounds comprising HAART, 
administered in a regimen of three or four drugs,25 alter the natural history of infection by 
affecting various phases of HIV propagation via mechanisms including disruption of 
reverse transcription,26 blockage of the requisite protease enzyme,27 prevention of host 
genome integration by viral DNA,28 and interference of HIV entry into the target cell.29 
Access to HAART in most high HIV prevalence areas, while improving, is still 
extremely limited – UNAIDS estimated in 2009 that just 36% of those indicated for 
HAART in low- and middle-income countries are receiving essential medications.30 
While vertical transmission, the means by which most children acquire HIV, can be 
prevented with antiretroviral monotherapy,31,32 complex regimens (e.g., HAART) are 
even more effective.33,34 However, just as overall HAART coverage is low, coverage of 
antiretroviral prophylaxis for HIV-infected pregnant women in low- and middle-income 
countries was estimated to be only 53% in 2009,30 meaning that new pediatric infections 
remain common. HAART has been proven as able to reduce an individual’s viral load to 
undetectable in both antiretroviral-naïve35,36 and -experienced35-37 patients, thereby 
severely limiting if not completely eliminating the devastating cycle of cell infection and 
destruction caused by HIV. Consequently, it follows that HAART would result in 
improved clinical and immunological outcomes. 
 
Clinical Progression and Survival Effects of Antiretroviral Therapy 
The beneficial effects of ART on the clinical progression and survival of HIV-
infected individuals have been established by numerous studies. Given that the first 
specific aim focuses on survival, an endpoint regularly examined in prior investigations 
 7 
of the effects of ART on clinical progression, it is apt to provide perspective on what is 
already known. 
The earliest randomized trials of ART evaluated a single drug, zidovudine (AZT), 
against placebo. A 1987 trial of 282 adult AIDS patients in the United States made clear 
the lifesaving promise of antiretroviral drugs – after between eight and 24 weeks of 
follow-up, there was one death in the AZT group compared to 19 deaths in the control 
group.38 The combined outcome of progression to AIDS or late stage disease was 
typically utilized by the influential studies of that time, all of which focused on adults. In 
a trial of 1,338 individuals in the United States aged 18 years or more with CD4 counts 
under 500 cells/μL, the rate of progression per 100 person-years, after a mean follow-up 
of 55 weeks, was 7.4 in the placebo group, 3.6 in the low dose AZT group, and 4.3 in the 
high dose AZT group.39 A trial of 993 asymptomatic individuals in Western Europe aged 
18 years or more, who had CD4 counts over 400 cells/μL and were followed for a median 
of 94 weeks, showed that AZT reduced progression – the hazard ratio (HR) for the 
comparison of AZT to no AZT was 0.56, with a 95% confidence interval (CI) of 0.43 to 
0.75.40 In a trial of 713 mildly symptomatic adults in the United States with CD4 counts 
between 200 and 800 cells/μL, the rate of progression per 100 person-years after a 
median follow-up of 11 months was 11.2 in the placebo group compared with 4.5 in the 
AZT group; correspondingly, 18-month progression-free survival was 91% with AZT 
and 81% without AZT.41 Given their clear demonstration of clinical benefits, these trials 
were instrumental in establishing AZT monotherapy as the first standard of care for 
pharmaceutical treatment of HIV, but they also made impossible any follow-up placebo-
controlled examination of the progression effects of AZT. Once AZT was known to delay 
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AIDS and death, further such investigation became unethical – in fact, three of the above-
cited trials39-41 were stopped. However, future studies, which would also inform changes 
in HIV treatment norms, offered additional evidence. 
The next set of trials evaluated monotherapy against dual therapy, and like the 
placebo-controlled AZT trials, found remarkably consistent results. The AIDS Clinical 
Trial Group (ACTG) 175 study followed 2,467 individuals in the United States aged 12 
years or more who had CD4 counts between 200 and 500 cells/μL, 43% of whom were 
antiretroviral-naïve.42 An analysis of all participants demonstrated that both the hazard of 
death (HR: 0.55; 95% CI: 0.36, 0.86) and the hazard of AIDS or death (HR: 0.64; 95% 
CI: 0.46, 0.87) were lower in the group treated with AZT+didanosine (ddI) than in the 
group treated with AZT alone; subgroup analyses of previously treated or untreated 
patients yielded similar findings. In a study of 1,418 previously untreated individuals in 
Western Europe, Australia, and New Zealand aged 15 years or more who were 
symptomatic or had CD4 counts under 350 cells/μL, adding ddI to AZT reduced the 
hazard of death (HR: 0.58; 95% CI: 0.45, 0.75) as well as the hazard of AIDS or death 
(HR: 0.64; 95% CI: 0.51, 0.79).43 An analysis of 735 individuals in the United States 
aged 13 years or more with CD4 counts under 200 cells/μL suggested that the addition of 
ddI to AZT reduced the hazard of death (HR: 0.62; 95% CI: 0.35, 1.08) and the hazard of 
AIDS or death (HR: 0.57; 95% CI: 0.36, 0.90).44 While no trials evaluated AZT against 
placebo in children, there was a pediatric trial to compare AZT to AZT+ddI, and the 
same trend as in adults was noted. In an analysis of 542 symptomatic or immunologically 
impaired children in the United States aged 18 years or less, more than 90% of whom 
were antiretroviral-naïve, adding ddI to AZT reduced the hazard of progression (defined, 
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for example, by weight-growth failure or development of at least two opportunistic 
infections) or death (HR: 0.61; 95% CI: 0.42, 0.88).45 Another trial of 596 antiretroviral-
inexperienced children in the United States aged less than 16 years evaluated ddI 
monotherapy against AZT+lamivudine (3TC), and found a lower hazard (HR: 0.37; 95% 
CI: 0.20, 0.67) of progression (death, new AIDS-defining illness, neurological decline, or 
weight-growth failure) and death (HR: 0.20; 95% CI; 0.06, 1.67) in the two-drug group.46 
Together, these trials demonstrated dual therapy as superior to monotherapy for slowing 
clinical progression and improving survival, and accordingly helped to usher in a new era 
of combination ART. 
Finally, dual therapy was compared to triple therapy (i.e., HAART). In a trial of 
151 antiretroviral-naïve, AIDS-free individuals in Europe, Canada, and Australia aged 18 
years or more with CD4 counts between 200 and 600 cells/μL, the proportion of patients 
who died or experienced a disease progression event during the 52 weeks of follow-up 
was smaller in the group receiving AZT+ddI+nevirapine (NVP) than in the group 
receiving AZT+ddI (12% versus 25%; p=0.08 by two-sided Fisher’s Exact Test).47 
Another trial assigned 1,313 individuals in the United States aged 13 years or more with 
CD4 counts below 50 cells/μL, 84% of whom were antiretroviral-experienced (generally 
with AZT monotherapy), to one of four treatment groups: AZT only, AZT+zalcitabine 
(ddC), AZT+ddI, or a HAART regimen of AZT+ddI+NVP.48 The time to death (41% of 
participants died during the median 65 week follow-up period) as well as AIDS or death 
was longer in the HAART arm than in either the AZT or AZT+ddC arms (p≤0.01 for all 
four comparisons) – HAART also extended survival times relative to AZT+ddI, although 
the study was not powered to detect a statistical difference. ACTG 320, a 1997 trial 
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conducted among 1,156 AZT-experienced individuals in the United States aged 16 years 
or more with CD4 counts less than 200 cells/μL, demonstrated that compared to 
AZT+3TC, the addition of indinavir (IDV) reduced both the hazard of death (HR: 0.43; 
95% CI: 0.19, 0.99) and the hazard of AIDS or death (HR: 0.50; 95% CI: 0.33, 0.76) by 
approximately 50% during the median 38 weeks of follow-up.49 This study, one of 
several to provide empirical support of the superiority of HAART over dual therapy for 
delaying AIDS and death which resulted in a new triple therapy standard of care, was 
suspended like other prior studies because it was deemed unethical to provide anything 
less than HAART to particular participants. These ethical considerations precluded 
additional trials on the progression effects of HAART; the fact that it was so successful at 
preventing AIDS and death meant that future trials did not focus on this research question 
– instead, they explored other themes, like the comparison of established and novel 
regimens of at least three drugs in terms of their virological and immunological 
effects,50,51 or the consequences of planned HAART interruption.52,53 
There were subsequent investigations of the clinical progression and survival 
impacts of ART, though they were restricted to non-randomized designs. These studies 
can be broadly categorized into two groups – those that utilized sufficient 
epidemiological methods, and those that did not (for discussion of why observational 
investigation of the causal effects of treatment requires specialized methods, see the 
Methodological context section of Chapter III, Research Methods). Next, the 10 studies 
to use optimal analytical techniques, which included antiretroviral-experienced 
individuals unless otherwise noted, will be reviewed. 
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The earliest methodologically sophisticated study evaluated 2,178 antiretroviral-
naïve men from the United States aged 18 years or more who were free of AIDS-defining 
illnesses, and found that AZT monotherapy reduced the hazard of death relative to no 
AZT (HR: 0.74; 95% CI: 0.57, 0.96).54 The next study was similar except for its focus on 
HAART rather than AZT. For 1,498 AIDS-free individuals in the United States aged 13 
years or more who were followed for a median of 5.4 years, HAART reduced the hazard 
of AIDS or death relative to no HAART (HR: 0.54; 95% CI: 0.38, 0.78).55 An analysis of 
the same population using different but still novel methods yielded an AIDS-free survival 
time ratio of 2.5 for the comparison of HAART to no HAART,56 a result consistent with 
the previously reported HR of 0.54. One study found that among women in the United 
States aged 13 years or more who had initiated HAART, the relative hazard of death 
attributable to HAART discontinuation was 1.97 (95% CI: 1.17, 3.31).57 Another found 
that HAART, relative to no ART, reduced the hazard of AIDS or death (HR: 0.74; 95% 
CI: 0.49, 1.12) in 917 Spanish adults followed for an average 3.4 years.58 The next, which 
analyzed 3,245 Swiss individuals aged 15 years or more, revealed a reduced hazard of 
death given HAART compared to no ART (HR: 0.14; 95% CI: 0.07, 0.29), and an 
attenuated but still strong effect compared to two-drug ART (HR: 0.49; 95% CI: 0.31, 
0.79).59 One analysis applied identical methods to 244 adults contemporaneously enrolled 
in two studies, and reached similar conclusions regarding the beneficial effect of HAART 
on survival, compared to less potent or no ART – the hazard ratios were 0.34 (95% CI: 
0.15, 0.77) and 0.27 (95% CI: 0.11, 0.66).60 A study published in late 2009 included 
nearly 63,000 antiretroviral-naïve individuals aged 18 years or more from 12 cohorts in 
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the United States and Europe, and found that HAART or less potent combination ART, 
relative to no ART, reduced the hazard of death (HR: 0.48; 95% CI: 0.41, 0.57).61 
The final two studies are unique for different reasons. The first is unique in its 
inclusion of individuals who are both from a resource-deprived setting and antiretroviral-
naïve. Among 14,267 South Africans aged 16 years or more, who were followed for a 
median of only four months (maximum 20 months), HAART reduced the hazard of death 
relative to no ART (HR: 0.14; 95% CI: 0.11, 0.18).62 The second is unique given its focus 
on children. Among 1,236 perinatally-infected individuals in the United States aged 21 
years or less, HAART reduced the hazard of death compared to less potent ART (HR: 
0.36; 95% CI: 0.19, 0.66).63 It is worth noting that when every one of the above datasets 
were instead analyzed using suboptimal methods, the revealed beneficial effect was either 
considerably less strong, or even harmful – this trend, at the very least, is highly 
suggestive of the inherent limitations of conventional analytic approaches. 
The vast majority of observational studies assessing the clinical progression and 
survival effects of ART, ranging from AZT monotherapy to HAART, have utilized 
standard methods. An analysis of 493 patients from an earlier trial39 who had begun AZT 
at various times following unblinding revealed that initiation of AZT greatly reduced the 
hazard of AIDS or death (HR: 0.17), but also that AZT offered no benefit after 2.1 years 
of treatment.64 These results were consistent with a study of 4,484 European adults. A 
multivariable Cox proportional hazards model adjusting for four baseline characteristics 
as well as time-varying Pneumocystis carinii (Pneumocystis jiroveci) prophylaxis yielded 
a lower hazard of mortality given AZT monotherapy relative to no AZT during the first 
(HR: 0.45; 95% CI: 0.41, 0.50) and second (HR: 0.78; 95% CI: 0.70, 0.88) years, but a 
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higher hazard after two years (HR: 1.24; 95% CI: 1.05, 1.47).65 In four other 
observational studies of adults,66-69 AZT monotherapy, relative to no AZT, reduced the 
hazard of clinical progression and/or survival to a similar degree as noted in comparable 
trials. In two analyses of sizeable adult populations that adjusted for prognostic factors 
such as CD4 count using time-dependent Cox proportional hazards models, two-drug 
ART was noted to reduce mortality compared with AZT only – the hazard ratio was 0.55 
(95% CI: 0.41, 0.74) for AZT plus either ddI or ddC versus AZT;70 0.79 (95% CI: 0.67, 
0.93) for AZT+ddI versus AZT,71 and 0.74 (95% CI: 0.59, 0.92) for AZT+ddC versus 
AZT.71 A methodologically similar study of 398 adults in the United States aged 20 years 
or more found that HAART reduced mortality (HR: 0.44; 95% CI: 0.28, 0.68), although 
it is unstated whether the referent group was naïve to HAART or all antiretrovirals.72 
Among adult patients in Brazil, after adjusting for CD4 count, HAART was noted to 
extend survival relative to one- or two-drug ART.73 
One compelling investigation was completed by Phillips et al.74 In this study, data 
from three large cohorts were used to mimic prior trials that had influenced HIV ART 
standards, including three evaluating AZT monotherapy against two-drug ART42-44 and 
two comparing two-drug ART to HAART.49 In general, analysis of the cohort data with 
traditional observational methods yielded estimates close to those from the trials, but one 
cohort dataset yielded a harmful effect of HAART on AIDS or death (HR: 1.20; 95% CI: 
1.01, 1.44) compared to a two-drug regimen, a result that starkly opposes the protective 
trial finding. This discrepancy, like the above noted trend of effect attenuation resulting 
from the application of suboptimal methods, reveals the potential for bias if observational 
data are not appropriately analyzed. 
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While trial data on the ART impacts of clinical progression and survival in 
pediatric populations are extremely limited, there are conventional observational studies 
of children in addition to the optimal one previously described.63 In a study of 1,028 
individuals in the United States aged less than 21 years who were followed for a 
maximum of four years, HAART reduced the hazard of death relative to less potent 
combination ART (HR: 0.33; 95% CI: 0.19, 0.58) according to a multivariable Cox 
proportional hazards model that accounted for baseline and time-varying factors75 A 
similar study, which followed 1,142 Italian children for a median of 5.9 years, found that 
monotherapy (HR: 0.77; 95% CI: 0.55, 1.08), two-drug ART (HR: 0.70; 95% CI: 0.42, 
1.17), and HAART (HR: 0.29; 95% CI: 0.13, 0.67) reduced the hazard of death compared 
with no ART.76 In a study of 107 Spanish children followed for a median of 65 months 
which adjusted for only CD4 percentage and age at HAART initiation in addition to 
gender, it was noted that HAART reduced the hazard of death (HR: 0.03; 95% CI: 0.01, 
0.14) relative no HAART, and that a lesser proportion of the group of children receiving 
HAART progressed to AIDS (26% versus 76%, p<0.01).77 
One recent pediatric HIV research area that is distinct from other studies of 
HAART, yet has still tangentially supported its beneficial effects on clinical progression 
and survival, is the question of whether HAART should be initiated in early or late 
infancy. A randomized trial demonstrated that among asymptomatic South African 
infants with CD4 percentages above 25%, mortality was reduced by 76% in those who 
started HAART before 12 weeks of age compared with those who initiated it later.78 This 
finding was echoed in an observational study of 210 European infants, which indicated 
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that deferring HAART increased the hazard of AIDS or death (HR: 3.0; 95% CI: 1.2, 
7.9).79 
Although ART has been consistently demonstrated to delay the clinical 
progression and improve the survival of HIV-infected individuals, knowledge on 
this relationship is not comprehensive. The aforementioned studies reveal various gaps, 
including a conspicuous scarcity of data on children – most research, whether prior to or 
during the HAART era, has been completed in adult populations in resource-privileged 
settings. Additionally, the stepwise historical progression from monotherapy to HAART 
has meant that placebo-controlled trials were limited to evaluation of a single-drug 
intervention, and that HAART has only been experimentally compared to less potent 
combination ART. In essence, there are no trials – which offer strong evidence, as 
“randomization is a powerful technique for ensuring valid causal inferences”80 – that 
directly assess the clinical progression or survival impacts of HAART vis-à-vis no ART 
in any population, even though this is a substantively important contrast. Although the 
randomized design is no longer ethically plausible, it is still possible to quantify the 
causal effects of HAART in an epidemiologically sound fashion using observational 
data.81 However, the prior observational studies quantifying how HAART affects survival 
that are most methodologically rigorous, and thus the source of the highest quality non-
experimental evidence, have been generally limited to the same types of populations as 
earlier trials. Only one such study – one of just two to offer the contrast of HAART with 
no ART – was completed outside of North America or Europe, and it focused on adults.62 
To date, there is just a single observational study of the effects of HAART on pediatric 
survival that has used the methods necessary to yield an effect measure defendable as no 
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worse than minimally biased, and that study included children in the United States who 
were antiretroviral-experienced if not receiving HAART.63 Other studies of children – all 
of which were completed in resource-privileged areas – used inadequate methods and 
hence provide information that, while potentially accurate, is inherently debatable in light 
of the possibility for bias previously noted. 
Another shortcoming is that studies designed to quantify the clinical progression 
and survival effects of ART rarely report effects across strata of immunodeficiency, 
despite associations between CD4 levels, opportunistic infections, and mortality. As 
highlighted, trial populations are often restricted to specific, narrow scopes of CD4 
values, such as under 200 cells/μL44 or 200 to 500 cells/μL,42 which prevents 
extrapolation beyond those ranges. While most studies that did not restrict based on CD4 
criteria simply present no more than an overall estimate, two methodologically ideal 
studies of adults additionally reported differential effects by level of immunodeficiency. 
One study revealed that HAART, compared to less potent ART, reduced the hazard of 
AIDS or death to a greater degree given a lower CD4 count – the HR was 0.36 (95% CI: 
0.20, 0.64) if the CD4 count was less than 200 cells/μL at baseline, 0.46 (95% CI: 0.27, 
0.81) if the CD4 count was between 200 and 350 cells/μL, and 0.82 (95% CI: 0.54, 1.27) 
if the CD4 count was more than 350 cells/μL.55 This trend was also evident in the South 
African study,62 which showed that HAART less profoundly improved survival relative 
to no ART when the analysis was restricted to those with baseline CD4 counts above 200 
cells/μL (HR: 0.33; 95% CI: 0.17, 0.64), as well as in the study of 63,000 adults,61 which 
revealed a stepwise reduction in the effect of HAART with increasing initial CD4 counts. 
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No studies of the clinical progression or survival effects of HAART in children present 
results by baseline level of immunodeficiency. 
The studies presented in this section collectively inform the hypothesis that 
HAART initiation, relative to non-initiation of HAART, will decrease the hazard of 
death. 
 
Immunological Effects of Antiretroviral Therapy 
The immunological effects of ART, like its effects on clinical progression and 
survival, have been extensively researched. This study’s second specific aim, which 
focuses on the immunological effects of HAART, necessitates appraisal of existing 
knowledge on this association. Because the questions of how ART affects clinical and 
survival outcomes and immunological markers of HIV infection are conceptually and 
substantively related, they are oftentimes investigated concurrently, and the histories of 
research on these subject areas logically run in parallel. That is, trial evidence on the 
immunological effects of ART also reflected (and shaped) the movement from 
monotherapy to two-drug therapy to HAART, with later observational studies – some 
methodologically stronger than others – addressing the effects of ART on CD4 levels. 
Most randomized trials of the clinical progression and survival effects of ART 
also examined immunological endpoints, including four previously described trials that 
evaluated AZT monotherapy against placebo. In two studies, AZT significantly increased 
CD4 counts relative to no AZT,38,39 while in another, it reduced the hazard of a CD4 
count decline to below 350 cells/μL by 40%.40 In the third trial, AZT increased CD4 
counts after six months among those with pre-randomization counts between 200 and 500 
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cells/μL (p=0.001), but not among those with a lesser degree of immunodeficiency 
(p=0.79).41 
Immunological outcomes were also evaluated in five previously described trials 
evaluating two-drug ART against AZT monotherapy. The first stratified by prior ART – 
among those previously treated, there was an increase in mean CD4 count from baseline 
over the first 32 weeks in the AZT+ddI and AZT+ddC groups, but a decrease in the 
group receiving AZT only; over longer follow-up, there was a decrease from baseline in 
all groups, but a larger decrease in the group receiving AZT only.42 Among those 
previously untreated, individuals in the two-drug groups had a mean increase in CD4 
count from baseline at most follow-up points, while those in the AZT group had a mean 
decrease at most follow-up points. An analogous pattern was noted in a separate but 
similarly designed trial.43 Another trial did not stratify by previous ART, but showed 
mean CD4 count increases at two months in the AZT+ddI (19.2 cells/μL) and AZT+ddC 
(12.9 cells/μL) groups but a decrease (-4.0 cells/μL) in the AZT only group.44 A trial in 
children demonstrated that at four weeks the mean CD4 percentage increased from 
baseline in the AZT+ddI group but not in the AZT only group (p<0.001); at 96 weeks, 
the AZT+ddI group had a 76% higher mean CD4 percentage than the AZT only group 
(p<0.001).45 Another pediatric trial noted that the mean CD4 count increase (72.9 
cells/μL) at weeks 36 to 48 increased more (p=0.01) given AZT+3TC than ddI only (3.6 
cells/μL).46 Other trials contrasting two-drug regimens with monotherapy examined 
immunological outcomes, including two that compared AZT only to AZT+3TC. In a 
study of 129 antiretroviral-naïve Europeans aged 18 years or more, the mean CD4 count 
increase after 24 weeks in the AZT+3TC group (80 cells/μL) was greater (p<0.001) than 
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that in the AZT only group (20 cells/μL).82 In a study of 366 North American adults, 
there was a greater 24 week increase in mean CD4 percentage (p<0.001) and count in the 
AZT+3TC group (p=.002 and 0.015 for low- and high-dose 3TC, respectively) than in 
the AZT only group, and these differences were durable over 52 weeks of follow-up.83 
HAART was shown to improve CD4 counts relative to two-drug ART in three 
previously cited trials. In the first, the mean increase in CD4 count after one year of 
follow-up was 52 cells/μL greater in the AZT+ddI+NVP group than in the AZT+ddI 
group.47 In the second, HAART improved the CD4 count to a greater degree after 16 
weeks than alternating monotherapy or either two-drug regimen (all p<0.001).48 And in 
the third, in strata of patients with severe (CD4 count less than 51 cells/μL) or moderate 
(CD4 count 51-200 cells/μL) immunodeficiency at ART initiation, two-drug ART led to 
a greater increase in CD4 counts at four, eight, 24, and 40 weeks than did 
AZT+3TC+IDV.49 
While there is limited trial evidence on the clinical progression and survival 
effects of HAART, there is plentiful such data on the immunological effects of HAART. 
Among 320 adults from the United States, Europe, and Australia with CD4 counts below 
50 cells/μL who had previously received AZT monotherapy, those randomized to 
HAART had a greater mean CD4 count increase (p<0.001) at 24 weeks (95 cells/μL) 
than those receiving AZT+3TC (6 cells/μL).84 In 97 patients who were similar but less 
immunodeficient (CD4 count between 50 and 400 cells/μL), the same conclusion was 
reached.85 One research group examined two different HAART regimens in 
antiretroviral-naïve adults from Europe, Australia, and Canada. In a study of 103 
individuals with CD4 counts between 150 and 500 cells/μL, there was a greater mean 
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increase in CD4 count at 52 weeks in the AZT+3TC+IDV group than in the AZT+3TC 
group (p=0.01).86 In a trial of 105 individuals, those receiving AZT+3TC+nelfinavir had 
a greater mean CD4 count increase (p=0.027) at 28 weeks (101.5 cells/μL) than those 
receiving AZT+3TC (47 cells/μL).87 In a trial of 297 children aged less than 18 years in 
the United States who were antiretroviral-experienced but naïve to both AZT and 3TC, 
those randomized to AZT+3TC+ritonavir (RTV) had a higher median CD4 percentage at 
48 weeks (p<0.01) than those randomized to RTV+stavudine (d4T).88 In a study of 162 
European and Brazilian children less than 17 years of age, adding 3TC to AZT+ddI, 
AZT+ddC, AZT only, or ddI only resulted in a mean CD4 count that was 48 cells/μL 
higher at 24 weeks (p=0.03).89 
Observational studies of the immunological response to ART, like those that 
quantify the effects of ART on clinical progression and survival, can also be categorized 
into two groups of methodological sophistication. However, while there are observational 
studies using standard methods to evaluate the effects of ART vis-à-vis less potent or no 
ART on clinical progression and survival, typical observational studies of immunological 
outcomes do not directly assess therapy against those referents. Rather, the norm is 
simply to observe changes in CD4 levels within a population that is uniformly receiving 
ART. These studies, whether conducted among adults or children, have provided 
extensive evidence for the ART-mediated improvement of immunological competency. 
For example, a study of 861 antiretroviral-naïve Spanish adults starting HAART showed 
an increase (p<0.001) in median CD4 count from 214 cells/μL to 499 cells/μL over a 
median of 173 weeks;90 among 57 children in the United States aged less than 16 years 
who were antiretroviral-experienced but HAART-naïve, initiation of HAART increased 
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the median CD4 count by 3% over 48 weeks.91 The paradigm of examining treated 
patients exclusively means that beyond the above cited randomized trials, the only other 
studies to quantify the immunological response to ART (versus less potent or no ART) 
were a limited number of observational investigations that employed adequate methods. 
To date, just five such studies have been completed. The first analyzed a 
population of 1,486 antiretroviral-naive adults in the United States to estimate that AZT 
monotherapy increased the CD4 count by 5.4 cells/μL (95% CI: -1.8, 12.7) every six 
months, compared to no AZT.92 The next included 1,763 men, 48% of whom were 
antiretroviral-experienced but HAART-naïve, from the same cohort.93 It was estimated 
that HAART relative to no HAART increased the mean CD4 count by 71 cells/μL in the 
first year and 29 cells/μL per year thereafter, with a greater first year gain in those with 
the lowest baseline CD4 counts. A similar study of 867 women showed not only that 
HAART improved the CD4 count at two years post-initiation, but also that the effect was 
stronger among those with more severe initial immunodeficiency.94 A study of South 
African adults,62 already described as it also examined survival, found that each month of 
HAART increased the CD4 count by 15.1 cells/μL (95% CI: 14.7, 15.5) over the first 19 
months, a result that was similar across strata of baseline immunodeficiency.62 The only 
analysis in children,95 a companion study to that which assessed the effect of HAART on 
survival in exactly the same population,63 found that HAART increased the mean CD4 
percentage by 2.34% (95% CI: 1.35%, 3.33%) over the first year relative to no HAART, 
that increases were sustained over five years, and that responses were most robust among 
those with the most profound immunodeficiency at baseline.95 As before, these studies all 
noted attenuated effects when traditional methods were applied to the same data, 
 22 
stressing the importance of appropriate analysis for any quantification of the 
immunological response to ART. 
Considering that the clinical progression, survival, and immunological effects of 
ART are biologically associated, and that investigations of these outcomes use related 
techniques and often identical study populations, it is unsurprising that the collective 
bodies of literature on these topics share many of the same shortcomings and limitations. 
The previously described gaps which characterize existing studies of the clinical 
progression and survival effects of ART – for example, a lack of methodologically strong 
observational studies comparing HAART to no ART in children, whether overall or 
within levels of immunodeficiency, and no studies of children in resource-deprived 
settings – are also evident in the scientific literature on the immunological effects of 
ART. These mutual deficiencies provide a common direction for future research into 
these substantially overlapping subject areas. 
The studies presented in this section collectively inform the hypothesis that 
HAART initiation, relative to HAART non-initiation, will increase the mean CD4 
percentage at all time points. 
 
Immunodeficiency at Antiretroviral Therapy Initiation: Clinical, Survival and 
Immunological Impacts 
While there is much known about the impact of immunodeficiency at time of 
ART initiation on clinical and immunological outcomes, the debate on when 
HAART should be started is not yet resolved, meaning that more information on 
these associations is needed. As the second specific aim of this study focuses on how the 
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immunological effects of HAART are influenced by category of CD4 percentage at 
baseline, with the third specific aim addressing whether the degree of immunodeficiency 
at HAART initiation is associated with recovery to “not significant” WHO age-specific 
immunodeficiency (see Table 2 for definition), it is pertinent to discuss the scope and 
implications of existing knowledge. Although this research does not examine the 
relationship between immunodeficiency and clinical progression or survival, this topic is 
included in the literature review for the sake of completeness and parallelism, and also 
because it remains only partially understood. 
In adults, greater immunodeficiency at the start of HAART has been linked to an 
increased likelihood of clinical progression and mortality. Progressively lower CD4 
counts were associated with reduced survival in four previously described studies, each 
of which contends that their results support not delaying HAART until the onset of severe 
immunodeficiency.72,90,96,97 An analysis explicitly completed to provide information on 
when HAART should be started in resource-deprived settings demonstrated that Thai 
adults with a baseline CD4 count less than 200 cells/μL had an elevated hazard of AIDS 
or death during the median 62 months of follow-up compared with those with a baseline 
CD4 count greater than 350 cells/μL (HR: 3.67; 95% CI: 1.31, 10.27).98 Fewer CD4 cells 
at HAART initiation has also been associated with reduced survival in a study of adults 
in South Africa;99 analyses of adults in the United States100 and more than 20,000 adults 
from 12 cohorts in Europe and North America101 revealed that more severe 
immunodeficiency at the start of HAART was associated with a higher hazard of AIDS 
or death. 
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Findings in children – mostly from sub-Saharan Africa, as there are few children 
starting HAART in the developing world – are generally concordant with those in adults, 
although there is sparser evidence, and some is conflicting. The previously described 
Zambian study102 revealed that the hazard of death was approximately doubled if children 
started HAART with a CD4 percentage under 20% rather than above 20%, while the 
study of children in Haiti103 showed that the hazard of death was higher in those with an 
initial CD4 percentage under 5% than in those with higher percentages (HR: 1.78; 95% 
CI: 1.38, 2.83). A study in Côte d'Ivoire also noted the danger of profound 
immunodeficiency, as the probability of survival 24 months after HAART initiation was 
72.8% given an initial CD4 percentage under 5% versus 97.8% otherwise.104 A pooled 
analysis of 2,405 children from 16 sub-Saharan African cohorts showed that initial World 
Health Organization (WHO) age-specific severe immunodeficiency,105 compared to 
lesser or no immunodeficiency, was independently associated with death over the median 
20.3 months of follow-up (HR: 2.57; 95% CI: 1.29, 5.12).106 However, results from 
several studies indicate that immunodeficiency at the start of treatment does not affect 
survival. The probability of survival at one and two years did not differ across strata of 
baseline immunodeficiency in a study of 586 children less than five years of age from 14 
sub-Saharan African countries,107 and an initial CD4 percentage under 5% was not 
associated with death among 151 South African children less than 16 years of age who 
were followed for a median of eight months.108 
It makes intuitive sense that the degree of immunodeficiency at the start of ART 
would influence eventual immunological outcomes. Insight on this association also 
contributes to the discussion of when HAART should be started, and it has been directly 
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examined, though there are relatively few studies with extended follow-up, particularly 
from resource-deprived settings or amongst children. One previously cited study of adults 
showed CD4 count gains, which leveled off after approximately three years, in each of 
four strata of baseline immunodeficiency.90 However, if the initial CD4 count was 
between 200 and 350 cells/μL, the likelihood of eventual immunological recovery (i.e., 
over 500 cells/μL) was reduced, with the chance of recovery even less if baseline 
immunodeficiency was more profound. In Australian adults, while the same relationship 
between initial CD4 count and immunological recovery at two years was noted, CD4 
count gains waned about two years after HAART initiation,109 the same point at which 
immune reconstitution slowed in 237 adults from the United Kingdom.110 Studies in the 
United States111 and the Netherlands,112 both of which conclude that HAART should be 
initiated earlier, yielded consistent results – less robust immunological recovery if the 
baseline CD4 count was less than 350 cells/μL, with no additional CD4 count gains after 
three to four years. One recent analysis, novel given its examination of long term CD4 
count trajectories among patients from resource-deprived areas, included 19,967 adults 
from 27 cohorts in sub-Saharan Africa, Latin America, and Asia and found that 
immunological recovery plateaued at roughly two years regardless of initial 
immunodeficiency. The authors of this study state that “baseline CD4 cell count was the 
most important determinant of subsequent CD4 cell count trajectories” and strongly 
contend that their data support starting HAART at higher CD4 counts.113 
Of the limited number of investigations of pediatric populations, only a minority 
examined long term immunological responses, with none of those studies completed in 
resource-deprived settings. A study of 1,012 children in the United States who were 
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antiretroviral-experienced, less than 18 years of age, and followed for up to three years 
revealed that those who started HAART with a CD4 percentage under 25%, while 
exhibiting gains that occurred over two years, failed to recover to the 25% level.114 
Another study in the United States had a median follow-up of 39 months and also showed 
that those with a baseline CD4 percentage under 25% increased but did not recover to 
25%, but it included a total of only 85 children and did not describe when CD4 gains 
ceased.115 In 177 children from Ireland and the United Kingdom who were antiretroviral-
naïve when starting HAART, each additional 5% in initial CD4 percentage raised the 
odds of attaining a CD4 percentage of 30% at six months (odds ratio [OR]: 2.60; 95% CI: 
1.76, 3.84); trends were apparently similar at 12 months although data were not 
presented.116 A study of 71 Dutch children presented a conflicting result – successful 
immune reconstitution independent of initial CD4 percentage – although few children 
were followed for the entire 96 week period and the distribution of baseline 
immunodeficiency was not presented.117 
Two previously cited studies examined immunological responses in children. The 
first, unique in its sub-Saharan African setting but limited in its duration of follow-up, 
noted that the probability of attaining a CD4 percentage of 25% one year after HAART 
initiation decreased with increasing baseline immunodeficiency.107 The second, unique in 
its long term assessment of outcomes, revealed that CD4 levels among children with 
immunodeficiency at baseline improved for two years after the start of HAART before 
stabilizing during the subsequent three years.95 It also showed while those with an initial 
CD4 percentage between 15% and 25% were able to recover to 25%, such recovery did 
not occur among those with an initial CD4 percentage under 15% even after five years, a 
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finding that “supports the initiation of HAART in children before severe 
immunosuppression occurs to maintain normal CD4 cell percentages.” 
It has been stated that understanding the associations between baseline 
immunodeficiency and eventual clinical and immunological outcomes would help to 
inform when HAART should be initiated, a claim that is substantiated by the authors of 
essentially every one of the preceding studies asserting that their respective findings 
should contribute to the ongoing debate. However, even those most ardently advocating 
for earlier initiation do not contend that results from these studies can alone impart 
change, not only because of the inherent potential biases of observational data such as 
confounding, but also because they do not precisely answer the question of when 
HAART should be started. That question is best addressed by a randomized trial 
comparing outcomes of individuals initiating HAART in a particular immunological 
range (e.g., CD4 count between 350 and 500 cells/μL) to those of individuals deferring 
HAART until advanced immunodeficiency. While such trials have not yet been 
completed,118 several recent studies have used observational data in concert with 
sophisticated methods that account for lead time bias and informative censoring in order 
to mimic trials assessing immediate versus deferred HAART.119,120 This work – along 
with a post-hoc analysis which allowed for a randomized contrast of HAART initiation 
above 350 CD4 cells/μL to below 250 CD4 cells/μL121 – has provided compelling 
evidence, in addition to that presented above, that HAART should be started in adults 
before the CD4 count falls below 350 cells/μL, as is currently recommended by WHO.122 
So, although there is increasing clarity on this issue in adults, the question remains far 
from resolved in children.123 
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The studies presented in this section collectively inform the hypotheses that 
children with greater immunodeficiency at HAART initiation will be less likely to 
recover immunologically, and that higher CD4 percentages at baseline will be associated 
with a reduced increase in CD4 percentage at all time points. The latter hypothesis is also 
informed by previously cited studies of the immunological effects of HAART in adults 
which examined the impacts of baseline CD4 levels.55,61,62 These hypotheses are also 
influenced by fact that CD4 levels at adjacent time points are logically connected – that 
is, it makes innate sense that those with lower baseline CD4 percentages will have lower 
CD4 percentages post-HAART, and that there is a narrower window for HAART-
mediated immunological improvement when CD4 percentages at baseline are higher. 
 
Summary and Rationale 
There is a general knowledge gap on the effects of ART on survival and 
immunological and clinical progression outcomes in HIV-infected children, with 
even less known among children in resource-deprived settings. Although research 
questions related to pediatric ART outcomes that are no longer feasibly answerable via 
randomized trial can now be addressed using observational data with specialized 
analytical methods, only two studies to date have utilized such an approach. The simple 
fact that the effects of HAART on survival and CD4 percentage, relative to no ART, have 
not been robustly quantified among children in a resource-deprived setting is alone 
sufficient to justify further research. Add the reality that questions remain about whether 
immunological responses to HAART are affected by baseline CD4 percentage, and there 
is ample opportunity and motivation for additional investigation. 
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It has been suggested that resource-deprived settings are typified by a distinct 
contextual milieu, but this theme has been explored in little detail. An article by De Baets 
et al.124 provides detailed description of this context and underscores realities commonly 
faced by pediatric HIV programs in Africa. These include challenges at the clinic level, 
such as limited diagnostic capacity, fewer drug options, dilapidated facilities, and 
suboptimal training, as well as challenges related to the patient and their environment, 
including delayed care seeking, concurrent comorbidities and undernutrition, and 
frequent loss to follow-up due to various poverty-related factors. Callens et al. highlight 
issues specific to the DRC, including food insecurity and inadequate health 
infrastructures.125 These factors collectively raise the possibility that the effects of 
HAART might not be heterogeneous in resource-deprived and -privileged settings; in 
fact, this has been observed in a meta-analysis of adults.126 The Antiretroviral Therapy in 
Lower Income Countries Collaboration points out that mortality after the initiation of 
HAART in low- and middle-income countries is higher than in high-income countries; 
UNAIDS speculates that is likely due to more advanced HIV upon presentation to care 
and a high incidence of co-occurring conditions.2 This example illustrates the danger of 
assuming equivalent effects of HAART in all children, and reveals the need for this 
research area to be explored in a resource-deprived setting. 
The impetus for this study is also built on the contention that additional specific 
knowledge in children is needed. Simply stated, HIV infection is not the same in children 
and adults. Following infection, because of deleterious effects of HIV on the immature 
thymus127 and heavy replication within the expanding lymphoid cell mass,128 children 
typically attain a higher peak viral load and correspondingly take longer to reach a 
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virological steady state than adults.129 However, although HIV can damage the thymus, 
children experience enhanced immunological recovery during HAART because the 
thymus is more active during childhood.130 This fact likely contributes to the results of a 
study which examined immunological responses of nearly 50,000 antiretroviral-naïve 
Europeans initiating HAART – after adjustment for potentially prognostic factors, 
individuals six to 29 years of age had a higher probability of response than those aged 30 
to 39 years, while individuals more than 60 years of age had a lower probability of 
response.131 These biological differences compel a need for research in children, just as 
profound differences in programmatic contexts compel a need for research in resource-
deprived settings. It cannot be assumed that observations in adults are applicable in 
younger populations, a sentiment perhaps best expressed in a study by the Pediatric 
ACTG group: “disease progression manifests itself differently in children… this often 
makes it inappropriate to extrapolate findings in adult studies to children.”24 
This work was completed to mitigate the incomplete understanding of the 
effects of HAART on survival and CD4 percentage in HIV-infected children, and to 
additionally inform the debate on when HAART should be initiated in terms of 
immunological status. It features sufficiently long follow-up and provides estimates of 
the effects of HAART to a lack thereof, a contrast that is relevant and prognostic because 
the majority of patients initiating HAART globally are antiretroviral-naïve, and unique 
because very few past studies in adults, and none in children, have presented that 
comparison. One study expressed that when data from randomized trials are not 
available, “observational data are often the best available evidence for assessment of 
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therapeutic effects”55 – in that spirit, with the tools necessary for proper analysis of the 
longitudinal observational data at hand, this research was pursued. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III. 
RESEARCH METHODS 
 
Study Design and Manuscripts 
The study’s aims – including estimation of the effects of HAART on survival and 
CD4 percentage in HIV-infected children – were pursued via analyses of longitudinal, 
observational, clinical cohort data from an ongoing comprehensive HIV care and 
treatment program in Kinshasa, DRC. This study produced two manuscripts. The first, 
entitled “The Effect of Highly Active Antiretroviral Therapy on the Survival of HIV-
Infected Children in a Resource-Deprived Setting: A Cohort Study” addresses Specific 
Aim 1. The second, entitled “Quantification of CD4 Responses to Highly Active 
Antiretroviral Therapy Among HIV-Infected Children in Kinshasa, Democratic Republic 
of Congo” addresses Specific Aims 2 and 3. 
 
Study Context 
As this study is ancillary to an existing program, context can be gleaned by 
examining the specifics of that initiative. Since 2003, with funding from the President’s 
Emergency Fund for AIDS Relief (PEPFAR) and the CDC Global AIDS Program, the 
University of North Carolina at Chapel Hill (UNC) has worked to improve HIV 
prevention and care in Kinshasa in collaboration with various international, national, and 
local partners including the Kinshasa School of Public Health, the National AIDS Control 
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Program, the Elizabeth Glaser Pediatric AIDS Foundation, the Belgian Development 
Cooperation, the Salvation Army, the William J. Clinton Foundation, the United Nations 
Children’s Fund, and the Global Fund to Fight AIDS, Tuberculosis, and Malaria. A 
cornerstone of that effort, and the source of data for this analysis, is an evidence-based, 
family-centered program which provides primary care, prophylaxis and treatment for 
opportunistic infections, and HAART (if indicated) to HIV-infected children and their 
first-line family members, pregnant and post-partum women and their HIV-exposed 
infants, and tuberculosis co-infected HIV patients at Kalembe Lembe Pediatric Hospital 
and Bomoi Healthcare Center. 
The program was implemented with various programmatic and research 
objectives. The programmatic objectives include evaluating the feasibility of 
comprehensive HIV care and treatment in Kinshasa, developing a sustainable and 
reproducible model for resource-deprived settings, providing community-based 
psychosocial support, sexual and reproductive health services, and nutritional counseling 
and support for participants and their families, and increasing local expertise of primary 
HIV care, specifically opportunistic infection and HAART management. The research 
objectives include estimating the incidence of antiretroviral toxicities and immune 
reconstitution syndromes, determining post-HAART changes in anthropometric 
parameters, observing adherence to HAART, and assessing the safety and utility of 
simplified laboratory monitoring. One research goal, to examine the clinical and 
immunological progression of individuals receiving HAART, is directly addressed by 
this study. 
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Study Population 
As the program is ongoing, to maximize the person-time and the number of 
children included in the analysis, datasets were finalized as late as possible. Patients 
enrolled through May 2010 were considered, with follow-up continuing through no later 
than August 2010. Between November 30, 2004, when the program began, and May 31, 
2010, a total of 3,445 individuals enrolled for care, 1,927 (55.9%) of whom were children 
(henceforth, “children” refers to those who were less than 18 years of age at the time of 
enrollment). Of the 1,360 individuals who initiated HAART by May 31, 2010, 770 
(56.6%, a figure nearly identical to the pediatric proportion of enrollees) were children. 
As of May 31, 2010, there were 2,303 active participants; 1,085 (47.1%) were children 
and 1,128 (49.0%) were receiving HAART. There were 600 children receiving HAART, 
meaning that 53.2% of those receiving HAART were children and 55.3% of children 
were receiving HAART. A total of 3,064.0 person-years had been accrued by children by 
May 31, 2010, with 1,793.6 (58.5%) of those person-years accrued during receipt of 
HAART. 
Because the focus of Specific Aims 1 and 2 was to estimate the effects of 
HAART relative to no HAART, it was necessary to exclude from the study population 
any children who were receiving HAART at time of program enrollment. To ensure that 
effect estimates represented those from an antiretroviral-naïve population, any children 
who were not receiving HAART at time of enrollment, but had received any ART 
previously, were also excluded. These criteria reduced the population negligibly. Also 
excluded were all children for whom documentation of confirmed HIV infection, by 
serology at age greater than 18 months or by viral load or DNA PCR, was lacking. This 
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criterion did result in the exclusion of a significant proportion of the 1,927 total enrolled 
children, not because of poor documentation, but because the program provides care to 
many HIV-exposed infants who are ultimately determined to be HIV-uninfected, at 
which time they are immediately deactivated. As in prior studies,55,63,93,95,132 complete 
baseline confounder data was required, and baseline could be shifted to the first visit with 
complete data. The only descriptor with non-negligible incomplete data at baseline was 
CD4 percentage; baseline was shifted in just 5.2% of children. Allowing follow-up to 
start at first CD4 rather than just at enrollment resulted in the inclusion of individuals that 
would have been otherwise excluded due to a single missing laboratory result. The final 
study population, once all exclusion criteria were applied, was comprised of 790 children 
who contributed a total of 2,089.8 person-years. HAART was started by 619 children 
(78.4%); children were receiving HAART during 1620.9 (77.6%) of the person-years. 
Eighty children (10.1%) died, 76 (9.6%) were lost to follow-up, 6 (0.8%) transferred care 
to another facility, and 628 (79.5%) were active at time of analysis. 
 
Figure 1. Flowchart of HAART and final dispositions (loss to follow-up, death, transfer 
of care to another facility, or active at time of analysis) for study population. 
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In the second manuscript, the Specific Aim 3 analysis was restricted to subset of 
the total population who initiated HAART and did so when immunodeficiency was mild, 
advanced, or severe. Similar to a prior study that used data from this cohort in which just 
12.2% of children who started HAART had “not significant” immunodeficiency,133 only 
13.4% of the 536 HAART initiators had “not significant” immunodeficiency. 
  
Patient Follow-up and Data Collection 
At each HIV care visit, participants were evaluated and demographic, clinical, and 
psychosocial data were collected as specified in the program protocol. According to this 
protocol, the initial decision whether HAART should be initiated was made one week 
following enrollment based on physician assessment and WHO105,134 and DRC135 
antiretroviral guidelines; if HAART was deferred, it could have been started at any 
subsequent visit if clinically indicated. The standard prescribed regimen was AZT or d4T, 
3TC, and NVP or efavirenz. If immunological treatment failure, toxicities, or potential 
drug interactions arose, patients were switched to alternative regimens. In analyses, 
patients switched to alternative regimens were still considered to be receiving HAART. 
Once initiated, HAART was never discontinued. Those receiving HAART were 
scheduled to visit monthly, while those not receiving HAART were scheduled to visit 
quarterly. Individuals needing acute medical care could also make unscheduled visits. 
Patients were lost to follow-up if they withdrew from care or could not be located by 
three tracking attempts following a missed visit. Specimens for CD4 count and 
percentage, assayed at the DRC National AIDS Reference Laboratory, were obtained at 
program enrollment and biannually thereafter. 
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Parental informed consent was obtained for all children; children at least 12 years 
age also provided their assent. In the consent forms, it was explicitly stated that collected 
data could be used for research. Data were collected using standardized paper forms and 
entered into a password-protected Microsoft Access database, which was securely 
transmitted on a monthly basis from Kinshasa to UNC. Routine and ad hoc procedures to 
identify and correct logically or biologically implausible values ensured a high degree of 
data quality prior to time of analysis. 
 
Methodological Context 
In the Clinical Progression and Survival Effects of Antiretroviral Therapy section, 
it is asserted that observational investigation of the causal effects of treatment is 
strengthened by specialized epidemiological methods, but no details are offered. The 
purpose of this section is to illustrate the reasons why that statement was made, as well as 
to provide the specifics of those methods, which figure prominently in the execution of 
the study. 
Observational data can present a number of analytical challenges. First, because 
exposure in a non-experimental study of treatment is not randomized like in a clinical 
trial, confounding by indication both at baseline and throughout the course of follow-up 
may result in substantial biases. Additionally, if the data are longitudinal, another 
scenario may further complicate estimation of an unbiased causal effect of an exposure 
on an outcome. This occurs when a particular factor is a common cause (confounder) of 
the exposure (at time t) and the outcome, while also a causal intermediate between the 
exposure (at times prior to t) and the outcome. 
 38 
It has been demonstrated in the presence of time-dependent exposures and factors 
that are simultaneously confounders and causal intermediates (hereafter referred to as 
time-dependent confounders affected by exposure), standard epidemiological methods for 
the estimation of causal effects are rendered inadequate.81,136 Several novel techniques to 
overcome this situation have been developed, including G-estimation of structural nested 
models137,138 and marginal structural models (MSMs).81 The most commonly applied 
approach is MSMs, as evidenced by their utilization in nearly all of the previously cited 
“methodologically sophisticated” studies.54-63,92-95 The parameters of an MSM – whether 
estimated via modification of linear, logistic, Cox proportional hazards, or other models – 
can be consistently obtained using estimators based on inverse-probability-of-treatment-
and-censoring (IPTC) weighting. 
Weighting is the underlying reason why the measure of effect produced by an 
MSM is causal rather than associational. While an IPTC-weighted model to estimate the 
parameters of an MSM is similar to other models in that it uses observed data to predict 
an outcome as a function of exposure and covariates, it is unlike other models in that it 
weights observations by the inverse of a joint probability of treatment and censoring that 
is unique for each individual at each point of follow-up. Application of IPTC weighting 
effectively removes any association of time-dependent confounders with subsequent 
exposure, thus creating a “pseudopopulation” unaffected by this phenomenon. Given that 
weighting does not modify the original causal association between exposure and 
outcome, the association between exposure and outcome in the “pseudopopulation,” 
assuming adjustment for baseline confounders, is therefore equivalent to the causal 
association between exposure and outcome in the original population. 
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Under the assumptions of consistency, positivity, and no model misspecification, 
unmeasured confounding, or informative censoring – most of which are empirically 
unverifiable – the measure of effect obtained from an MSM is causal.81,139 The exact 
interpretation depends on the type of model. For example, the effect measure from a Cox 
proportional hazards MSM is the log hazard ratio comparing the hazard of the outcome 
had all individuals been continuously treated since baseline to the hazard had they never 
been treated during follow-up, while that from a linear MSM represents the mean change 
in the outcome had all individuals been continuously treated since baseline compared to 
that had they never been treated during follow-up. Though derived from the observed 
outcomes of individuals experiencing exposed and unexposed person-time, contrasts 
from MSMs (while causal) are ultimately hypothetical given that IPTC weighting 
transforms an associational model into a model for counterfactual outcomes in the source 
population. 
This study’s first specific aim was to estimate the causal effect of HAART on 
survival, and its second specific aim was to estimate the causal effect of HAART on 
mean change in CD4 percentage. The following directed acyclic graph (DAG)140 – a 
causal diagram that depicts assumed relationships between an exposure, an outcome, and 
other related factors – is illustrative for both aims. It shows that there is a time-dependent 
exposure (HAART), and reveals the structural contribution of a time-dependent 
confounder affected by exposure, several of which are believed to figure into the 
associations between HAART and study outcomes. Thus, in order to best elucidate the 
causal effect of HAART on 1) survival, and 2) CD4 percentage change, this analysis used 
weighted regression models to estimate the parameters of MSMs. 
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Figure 2. Directed acyclic graph representing the causal effect of time-dependent 
HAART on study outcomes. 
 
 
 
Numeric subscripts 0 and 1 denote the enrollment visit and subsequent visits, 
respectively. Measured time-dependent confounders affected by exposure and 
unmeasured causal risk factors (i.e., non-confounders) for the study outcomes are shown. 
For clarity, factors that are baseline confounders (i.e., not time-dependent confounders 
affected by exposure) are not shown.
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Analysis – Specific Aim 1 
The study’s first specific aim, to estimate the causal effect of HAART on 
survival, was pursued via Cox proportional hazards MSMs. Because most software 
packages cannot accommodate subject-specific time-varying weights in the fitting of Cox 
models, parameters of Cox proportional hazards MSMs are typically approximated via 
weighted pooled logistic regression.54,55,58-63,133 The parameters of a Cox model, whether 
the model is weighted or not, are well approximated by pooled logistic regression when 
the hazard of the outcome per person-time interval is small,141 as is the case in this study. 
Let D(t)=1 if an individual experienced the outcome between visit (t-1) and visit t 
and D(t)=0 otherwise. Let the A(t) represent an individual’s HAART status at visit t; let 
a(t)=1 if an individual initiated HAART at or before visit t and a(t)=0 otherwise. Let Ā(t) 
represent an individual’s HAART history up to visit t; let ā(t) be HAART history up to 
visit t. Let L(0) represent the vector of baseline confounders; let l(0) be the vector of 
baseline confounders observed. Let L(t) represent the vector of time-dependent 
confounders affected by exposure; let l(t) be this vector observed at visit t. Let C(t)=1 if 
an individual is censored between visit (t-1) and visit t, and C(t)=0 otherwise, where an 
individual is censored if they are lost to follow-up or have not experienced the outcome at 
the end of study. k denotes days since the start of follow-up. 
Using weighted pooled logistic regression – where individuals’ contributions to 
the risk set at each visit t are weighted by the subject- and time-specific stabilized 
weights swi(t) – the following model was fit, where β0(t) is a time-dependent intercept: 
(1) logit pr[D(t) = 1 | D(t-1) = 0, Ā(t-1), L(0)] = β0(t) + β1A(t-1) + β2L(0) 
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The time-dependent intercept, wherever noted, was modeled using restricted cubic 
splines with four knots at the 5th, 35th, 65th, and 95th percentiles of time, per precedent.55,93  
The stabilized weight swi(t), most easily conceptualized as an inverse-probability-
of-treatment-and-censoring weight, is not simply the product of an inverse-probability-of-
treatment weight and an inverse-probability-of-censoring weight. More specifically, 
swi(t) is the product of the following: 1) the conditional probability that an individual 
received their own exposure at visit t given their exposure history and baseline 
confounders, divided by the conditional probability that the individual received their own 
exposure at visit t given their exposure history and baseline and time-dependent 
confounders affected by exposure, and 2) the conditional probability that the individual 
was uncensored at visit t given their exposure history and baseline confounders, divided 
by the conditional probability that the individual was uncensored at visit t given their 
exposure history and baseline and time-dependent confounders affected by exposure. 
Thus, as outlined by Hernán et al.,54  
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This subject- and time-specific weight is stabilized, meaning that the numerator of each 
of the terms in the above equation is as depicted, rather than equaling 1 (which would 
produce a non-stabilized weight). Stabilized weights have been shown to yield less 
variable and no less biased parameters than non-stabilized weights.81 Applying time-
dependent weights to model (1) induces within-subject correlation, necessitating the use 
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of robust variance estimators (i.e. generalized estimating equations with an independent 
working covariance matrix).54 
It is necessary to fit four logistic models to obtain swi(t), needed to weight model 
(1). The first model, fit only using those observations representing visits at which 
individuals have not yet initiated HAART or have just been assigned HAART, features 
HAART as the outcome and the baseline confounders and time-dependent intercept as 
predictors. This model yields a predicted probability of remaining off HAART for each 
of the non-HAART or first HAART visits. For each individual, this probability for visit t 
is multiplied by that for all previous times, leading to the conditional exposure probability 
in the numerator of the stabilized weight. 
The second model is identical to the first, except for that the time-dependent 
confounders affected by exposure are added as predictors. The predicted probabilities 
from this model, while analogous to those of the first model, instead contribute to the 
conditional exposure component of the stabilized weight denominator. The third model, 
which uses all observations, features the censoring indicator as the outcome and the 
HAART indicator, baseline confounders, and the time-dependent intercept as predictors. 
Hence, the predicted probabilities of remaining uncensored obtained from this model 
contribute to the conditional censoring component of the stabilized weight numerator. 
The fourth model is identical to the third, except for that the time-dependent confounders 
affected by exposure are added as predictors – the predicted probabilities contribute to 
the conditional censoring component of the stabilized weight denominator. In these four 
models, the time-dependent intercept reduces the number of free parameters, leading to 
reduced variability necessary for consistent IPTC estimation.142 
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A stabilized weight is obtained for each observation by dividing the product of the 
numerator components by the product of the denominator components. Then, with each 
observation in the pooled dataset weighted by its respective stabilized weight, model (1) 
is fit using robust variance to account for induced clustering. As previously described, the 
resultant exposure parameter is equivalent to the log hazard ratio comparing the hazard of 
the outcome had all children continuously received HAART since baseline to the hazard 
had they never initiated HAART. 
 It has been demonstrated that a dynamic visit schedule, evident in this HIV 
program because patients visited more regularly if they were receiving HAART and 
could also visit when acute care was needed, can induce biases in longitudinal studies of 
time-varying treatment.143 Thus, in addition to the customary IPTC-weighted model, an 
alternative weighted model was used. The weight in this model was the IPTC weight, as 
described above, multiplied by a visit attendance weight, to yield an inverse probability 
of treatment, censoring, and visit attendance (IPTCV) weight. The numerator and 
denominator models for having a visit were identical for those for the censoring weight 
models, besides their inclusion of one additional predictor: time since last visit. 
A DAG informed by previous related analyses55,62,63,93,95,133 and a priori 
knowledge was used to identify the included baseline confounders (age, gender, and 
WHO HIV clinical stage and severity of immunodeficiency) and time-dependent 
confounders affected by exposure (CD4 percentage, HIV-related symptom or condition, 
and cotrimoxazole), which are detailed in Table 2. This strategy was empirically 
supported, assuming that the causal diagram was correctly specified.144 The pooled 
dataset included one observation per person-day. If information was missing for a time-
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dependent covariate, it was be filled by the most recently observed prior value (whether 
at a scheduled or unscheduled visit), as is standard.62,63,93,95,132 For example, if a child was 
observed on days one and four, data for the “missing” days two and three were filled 
from day one. 
At baseline, the total study population (as well as the subsets of children who 
eventually initiated or did not initiate HAART) was described in terms of variables in 
Table 2 – e.g., the number and percentage of children in each immunodeficiency 
category, and the median and interquartile range (IQR) for CD4 percentage, were 
calculated. These groups were also characterized in terms of other descriptors, including 
person-years contributed, median duration and IQR of follow-up, median number and 
IQR of program visits, and outcomes including death and deactivation due to transfer of 
care to another facility or loss to follow-up. Proportions were compared via the mean 
score or chi-square test, as appropriate, and medians were compared via the Mann-
Whitney test. Mortality rates, rate ratios, and 95% CIs were calculated via Poisson 
regression. 
Associations between HAART initiation and both baseline confounders and time-
dependent confounders affected by exposure, produced by the logistic model to obtain 
the denominators for the inverse-probability-of-treatment weights, were examined. As in 
methodologically comparable studies,54-63,92-95 to demonstrate whether gains in estimate 
validity were afforded by the utilized analytical approach, MSM results were directly 
compared to methods that do not appropriately account for time-dependent confounders 
affected by exposure (e.g., unweighted time-dependent Cox proportional hazards 
regression). Models that included an interaction term between categorical time and 
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HAART were used to assess the constancy of HRs during follow-up. To visualize the 
effect of HAART on survival, Kaplan-Meier curves were constructed, with unstratified, 
unconditional IPTCV-weighted curves generated using unstabilized weights.145 Estimates 
of cumulative incidence were depicted by plotting the compliments of Kaplan-Meier 
curves. The timing of HAART initiation, as well as the decreasing size of the study 
population over time due to transfer of care to another facility, loss to follow-up, and 
death, was also illustrated. 
 
Analysis – Specific Aim 2 
Although the focus of Specific Aim 2 was to estimate the causal effect of HAART 
on CD4 percentage rather than death, there was substantial methodological overlap with 
Specific Aim 1. Commonalities included the same baseline confounders and time-
dependent confounders affected by exposure, specification of time as days, carrying data 
forward, and fitting of weighted models with robust variance. Thus, for the sake of 
concision, this section highlights the precise areas in which the analysis differed from that 
already described. 
As in the survival analysis, MSMs were a central component. However, there was 
an essential difference – instead of estimating the parameters of Cox proportional hazards 
MSMs via weighted pooled logistic regression, the parameters of MSMs were estimated 
via repeated measures linear regression, as in previous studies.62,92,93,95,132 While 
stabilized IPTC weights were again derived via four pooled logistic models, with six 
models used to generate IPTCV weights, weights were applied not to model (1), but 
instead to model (2): 
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(2) E[Y(t) | Ā(t), L(0)] = β0(t) + β1Z(t) + β2L(0) 
E[Y(t)] represents CD4 percentage at time t and Z(t) represents cumulative HAART 
exposure as of time t. Examination of previous studies93,132 informed how Z(t) was 
categorized (see Variables section). Within-subject correlation resulting from repeated 
observations of individuals were accounted for by using generalized estimating equations 
with an independent working correlation matrix, per precedent.92,93,95,132 This model 
yielded the mean difference in CD4 percentage had all individuals continuously received 
HAART since baseline compared to that had they never received HAART during follow-
up. 
As CD4 percentage was assessed biannually, although program visits were 
scheduled either monthly or quarterly, model (2) was fitted using only observations with 
a measured CD4 percentage result. If HAART was started at a visit where CD4 
percentage was not measured, the precise time of initiation nonetheless informed the 
cumulative HAART exposure variable (i.e., cumulative exposure was coded as “>0 to 6 
months” if HAART began 90 days prior to CD4 assessment). 
In addition to the overall effect of HAART on CD4 percentage at six month time 
points, the effect within categories of baseline CD4 percentage was estimated by fitting 
stratum-specific models as in the studies by Hernán et al.61 and Fairall et al.62 Mean 
changes in CD4 percentage were presented graphically, as were the durations of HAART 
and the number of CD4 percentage measurements during each of the six month periods. 
The observed evolutions in CD4 percentage for children receiving HAART and children 
not receiving HAART were also depicted using box plots. 
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Analysis – Specific Aim 3 
To determine whether the degree of immunodeficiency at HAART initiation was 
associated with recovery to “not significant” WHO age-specific immunodeficiency, the 
immunodeficiency categories as defined by WHO guidelines105 and outlined in Table 2 
were first collapsed into two groups: mild plus advanced, and severe. An HR for the 
time-to-event outcome of recovery to “not significant” immunodeficiency was estimated 
via Cox proportional hazards regression, with the proportional hazards assumption 
verified by visually inspecting log-negative-log survival estimates. Kaplan-Meier curves were 
generated to examine the survival functions of the two severity of immunodeficiency 
groups, with the log-rank test used to assess differences between groups. Time started at 
HAART initiation and ended at the first of loss to or end of follow-up, transfer of care to 
another facility, death, or attainment of “not significant” immunodeficiency. A published 
SAS macro was used to construct cumulative incidence curves.146 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV. 
THE EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON THE 
SURVIVAL OF HIV-INFECTED CHILDREN IN A RESOURCE-DEPRIVED 
SETTING: A COHORT STUDY 
 
Abstract 
 
Background 
The effect of highly active antiretroviral therapy (HAART) on the survival of 
HIV-infected children has not been well quantified. Because most pediatric HIV occurs 
in low- and middle-income countries, our objective was to provide a first estimate of this 
effect among children living in a resource-deprived setting. 
 
Methods and Findings 
Observational data from HAART-naïve children enrolled into an HIV care and 
treatment program in Kinshasa, Democratic Republic of Congo between December 2004 
and May 2010 were analyzed. We used marginal structural models to estimate the effect 
of HAART on survival while accounting for time-dependent confounders affected by 
exposure. At the start of follow-up, the median age of the 790 children was 5.9 years, 528 
(66.8%) had advanced or severe immunodeficiency, and 405 (51.3%) were in HIV 
clinical stage 3 or 4. The children were observed for a median of 31.2 months and 
contributed a total of 2089.8 person-years. Eighty children (10.1%) died, 619 (78.4%) 
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initiated HAART, six (0.8%) transferred care, and 76 (9.6%) were lost to follow-up. The 
mortality rate was 3.2 deaths per 100 person-years (95% CI: 2.4, 4.2) during HAART and 
6.0 deaths per 100 person-years (95% CI: 4.1, 8.6) during receipt of primary HIV care 
only. The mortality hazard ratio comparing HAART to no therapy from a marginal 
structural model was 0.25 (95% CI: 0.06, 0.95). 
 
Conclusions 
HAART reduced the hazard of mortality in HIV-infected children in Kinshasa by 
75%, an estimate that is similar in magnitude but with lower precision than the effect of 
HAART on survival that has been reported among children in the United States. 
 
Introduction 
Highly active antiretroviral therapy (HAART) clearly improves the survival of 
adults living with HIV25,147 even when initiated at higher CD4 cell counts,119,120 but less 
is known about the degree to which HAART affects the survival of HIV-infected 
children. The course of HIV disease in children, due in part to deleterious impacts of the 
virus on the immature thymus127 leading to high HIV RNA viremia129 and rapid death,148 
is distinct from that in adults.24 Response to antiretroviral treatment also differs across 
age groups.131 Given that the natural history of HIV and response to therapy vary by age 
and that over two million children worldwide are living with HIV,2 the extrapolation of 
results from studies of adults to pediatric populations is not appropriate. It is imperative 
that the effect of HAART on survival be quantified specifically in children. 
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Most observational studies of the effects of treatment on survival in children have 
not used the epidemiological methods necessary to account for potential biases inherent 
to their design, including confounding by indication. One study not employing those 
methods found that HAART, relative to no therapy, decreased the mortality rate by 71% 
among 1,142 Italian children.76 A recent study of 1,236 children in the United States,63 
which used optimal analytical methods, observed a result similar to that from the Italian 
study. 
Greater than 90% of children receiving HAART live in low resource areas.2,149 
Because multiple factors that may affect adversely treatment outcomes including delayed 
presentation to care and a higher incidence of co-occurring conditions are more common 
in such environments,150 there is a specific need for information on the effects of HAART 
on patients living in these areas. Studies in adults have shown higher mortality after 
HAART initiation in resource-poor settings than in resource-privileged settings after 
adjusting for age, CD4 cell count, and disease stage.126,151 Although investigations in 
pediatric cohorts from Zambia102 to Haiti103 to Côte d'Ivoire104 have shown that treatment 
improves immunological, hematological, and growth outcomes and results in mortality 
rates lower than those observed in the pre-antiretroviral era,148 the effect on mortality of 
HAART itself has never been accurately quantified among children in a resource-
deprived setting. This is true of two recent multi-site studies in sub-Saharan Africa, 106,152 
as well as studies in Thailand,153 Zambia,154 Côte d'Ivoire,155 and Lesotho156 that have 
provided valuable information on mortality among children receiving HAART, including 
rates during the early and late therapeutic periods. 
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In this study, we investigated the effect of HAART on mortality in an 
observational clinical cohort of HIV-infected children in the Democratic Republic of 
Congo (DRC). As HAART is typically initiated in sicker patients, for example those with 
lower CD4 cell percentages, it is necessary to adjust for this confounding by indication to 
estimate its effect on survival. But adjusting for a time-dependent factor such as CD4 cell 
percentage that is itself affected by prior HAART exposure can yield a measure not 
interpretable as the total effect of HAART, because the effects of therapy are mediated in 
part through CD4. We therefore used a method that adjusts for time-dependent 
confounding by indication while accounting for confounders affected by prior exposure, 
marginal structural models (MSMs). 
 
Methods 
 
Ethics Statement 
Parental informed consent for the HIV care program, in addition to assent from 
minors at least 12 years of age, was obtained for all participants. All research was 
conducted according to the principles expressed in the Declaration of Helsinki and was 
approved by the Ethics Committee of the Kinshasa School of Public Health (approval 
numbers ESP/CE/010 and ESP/CE/014) and the University of North Carolina at Chapel 
Hill Institutional Review Board (study numbers 04-1007, 05-2311, and 10-0661). 
 
Study Population, Measurements, and Follow-up 
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The source of information for this study was a comprehensive HIV care and 
treatment program serving children and family members at Kalembe Lembe Pediatric 
Hospital and Bomoi Healthcare Center in Kinshasa, DRC.133 HIV infection was 
confirmed by serological testing, with HIV viral load or DNA PCR used in infants under 
18 months of age. Patients were managed in accordance with World Health Organization 
(WHO)105,134,157 and national135 guidelines regarding diagnosis and treatment of 
opportunistic infections, laboratory monitoring, and provision of cotrimoxazole and 
HAART when clinically or immunologically indicated. HAART could be initiated as 
soon as one week following enrollment or at any visit thereafter, with the standard first-
line regimen comprised of zidovudine or stavudine, lamivudine, and nevirapine or 
efavirenz. Because virological diagnostics were occasionally unavailable, enrolled infants 
under two years of age did not always begin treatment immediately as recommended by 
WHO.157 Visits were scheduled monthly for patients receiving HAART and quarterly for 
those not receiving HAART, with additional unscheduled visits made by individuals 
needing acute care. Clinical data, documented by physicians during patient visits using 
standardized forms, were collected. CD4 cell count and percentage were evaluated every 
six months at the DRC National AIDS Reference Laboratory, but viral load was not 
routinely assessed due to infrequent availability of the assay. 
The population for this analysis was HIV-infected children who were naïve to 
antiretroviral therapy and under 18 years of age at the start of follow-up. The beginning 
of follow-up, also referred to as baseline, was the initiation of HIV care (between 
December 2004 and May 2010) unless a child’s CD4 percentage was not obtained at that 
visit, in which case baseline was defined as the date of the first available CD4 percentage 
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result. Consistent with precedent,63,93 allowing follow-up to start at first CD4 meant that 
children did not have to be excluded due to missing immunological data. Follow-up 
ended at death or at the last clinic visit prior to transfer of care, loss to follow-up, or 
August 2010. If children withdrew from care or could not be located by three tracking 
attempts after a missed visit, they were classified as lost to follow-up. Children 
contributed non-HAART person-time until they initiated HAART. Program personnel 
gathered information on children who died, including the date and suspected cause of 
death. 
 
Statistical Analysis 
Mortality rates were expressed as deaths per 100 person-years, with rates and rate 
ratios calculated via Poisson regression. To compare proportions, we used the chi-square 
or mean score test, while medians were compared by the Mann-Whitney test. SAS 
version 9.2 (SAS Institute, Cary, NC) was used for all analyses. 
To estimate the total effect of HAART on mortality, one must adjust for 
confounders measured at baseline as well as time-varying confounders affected by prior 
exposure, factors that are causal intermediates between treatment and death while 
simultaneously common causes of subsequent treatment and death.81 We did so by fitting 
four logistic regression models to predict subject and time-specific probabilities of 
treatment and censoring as a function of covariate histories, and using these predicted 
probabilities to construct stabilized inverse-probability-of-treatment-and-censoring 
(IPTC) weights. The model for the denominator of the treatment weight included as 
independent variables baseline confounders, time-varying confounders affected by 
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exposure, and time, while the model for the treatment weight numerator included only 
time and baseline confounders. The models for the censoring weight numerator and 
denominator were identical to those for the treatment weights, except that the censoring 
models also included time-varying HAART as a predictor. Then, these IPTC weights 
were used in a weighted pooled logistic model, which included baseline confounders, to 
estimate the parameters of a Cox Proportional Hazards MSM.54,158 Assuming no 
unmeasured confounding, informative censoring, or model misspecification, weighting 
disassociates time-varying confounders with subsequent treatment and censoring, 
effectively eliminating the causal intermediates complicating estimation of the effect of 
HAART on mortality. With the intent-to-treat assumption that children starting HAART 
received it uninterruptedly throughout follow-up, approximately true in our program 
because adherence was checked at every visit and treatment was never discontinued for 
active patients, the MSM yields a hazard ratio (HR) comparing the hazard of death had 
all children initiated HAART to that had no children initiated HAART during follow-up. 
For comparison, we also fit unadjusted as well as adjusted but unweighted pooled 
logistic models. Additionally, to address possible bias resulting from the dynamic visit 
schedule,143 we utilized an alternative weighted model which employed the above 
described IPTC weight multiplied by a visit attendance weight, that is, an IPTCV weight. 
The models for the probability of having a visit were equivalent to the censoring weight 
models, except for time since last visit was also included as a predictor. The constancy of 
HRs over follow-up was assessed with models that included an interaction term between 
HAART and categorical time. Kaplan-Meier curves to visualize the impact of HAART 
on survival were constructed; unstabilized weights were used to obtain unconditional, 
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unstratified IPTCV-weighted curves.145 The complements of Kaplan-Meier curves were 
plotted as estimates of cumulative incidence. 95% confidence intervals (CIs) for MSM 
HRs were based on robust variance to account for within-subject correlation induced by 
weighting. Our pooled dataset included one row per person-day, with missing covariate 
data carried forward from last observation. 
Confounders were selected based on a posited causal directed acyclic graph140 and 
previous studies. Baseline confounders were WHO HIV clinical stage and severity of 
immunodeficiency, age, and gender; time-varying confounders affected by prior exposure 
were cotrimoxazole prophylaxis, HIV-related symptoms or conditions, and CD4 cell 
percentage. HAART, gender, cotrimoxazole, and symptoms or conditions were coded 
dichotomously. HIV-related symptoms or conditions included one or more of the 
following: Kaposi’s sarcoma, oral or esophageal candidiasis, severe weight loss, 
tuberculosis, fever or diarrhea of one month or more, lymphocytic interstitial or 
Pneumocystis jirovecii pneumonia, chronic herpes simplex, oral hairy leukoplakia, 
cryptococcal meningitis, toxoplasma or HIV encephalopathy, or HIV-associated 
nephropathy. Because it was generally assessed only at enrollment, clinical stage was that 
at HIV care initiation for all children, including those for whom follow-up began at first 
CD4 result. Severity of immunodeficiency was calculated according to WHO 
guidelines105 using CD4 and age at baseline. Both clinical stage and severity of 
immunodeficiency were coded into four levels and treated as indicator variables in 
multivariable analyses. CD4 percentage, age, and time were modeled as restricted cubic 
splines with four knots, at the 5th, 35th, 65th and 95th percentiles. 
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Results 
Characteristics of the 790 children at baseline are shown in Table 1. The median 
age was 5.9 years (interquartile range [IQR]: 2.7, 9.8), and roughly one-half were female 
(52.5%). The majority of patients had severe immunodeficiency (57.2%) as reflected in 
the low median CD4 percentage of 15 (IQR: 9, 22). Most children had advanced HIV as 
indicated by clinical stage 3 or 4 (51.3%), and 19.9% had evidence of at least one HIV-
related symptom or condition. 
The 790 children, 619 of whom initiated HAART (78.4%) during follow-up, were 
followed for a median of 31.2 months (IQR: 10.3, 53.6) and had a median of 30 HIV care 
visits (IQR: 11, 57). Of those who started treatment, 110 (17.8%) switched to an 
alternative regimen due to an adverse event or treatment failure. At baseline, compared to 
those who remained untreated, children who later initiated HAART had greater degree of 
immunodeficiency (p<0.01) with a corresponding lower median CD4 percentage 
(p<0.01), more advanced HIV clinical stage (p<0.01), and were more likely to have at 
least one symptom or condition (p<0.01). Those who initiated HAART were similar to 
those who did not in terms of gender (p=0.05) and median age (p=0.17) as well as 
cotrimoxazole initiation at the beginning of follow-up (p=0.05). The median duration of 
observation for children who started HAART, 36.9 months (IQR: 14.0, 55.7) with 31.3 of 
those months (IQR: 11.4, 52.0) during receipt of HAART, was longer than the median 
11.5 months (IQR: 3.0, 27.0) observed for untreated children (p<0.01), and there was a 
parallel difference in median number of visits (40 versus 9, p<0.01). 
Eighty children (10.1%) died during the 2089.8 accrued person-years of follow-
up, an overall mortality rate of 3.8 deaths per 100 person-years (95% CI: 3.1, 4.8). The 
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unadjusted mortality rate ratio comparing HAART to the lack thereof was 0.54 (95% CI: 
0.34, 0.85). There were 51 deaths during the 1620.9 person-years (77.6% of total follow-
up) contributed by children receiving HAART, a rate of 3.2 deaths per 100 person-years 
(95% CI: 2.4, 4.2), and 29 deaths during the 468.9 non-HAART person-years, a rate of 
6.0 deaths per 100 person-years (95% CI: 4.1, 8.6). The mortality rates per 100 person-
years during and after the first 90 days of HAART were 16.4 (95% CI: 11.0, 24.5) and 
1.8 (95% CI: 1.3, 2.7), respectively. The proportion of HAART-untreated children who 
died (17.0%) was higher than the 8.2% of HAART-initiating children who died (p<0.01), 
and the absolute three-year risk of death for children receiving HAART was 0.14 
compared with 0.48 for children not receiving treatment. Thus, the unadjusted HAART 
mortality risk ratio was 0.31 (95% CI: 0.23, 0.43). Six children (0.8%) transferred care 
and 76 (9.6%) were lost to follow-up. A smaller proportion of children who initiated 
HAART (7.9%) than untreated children (19.3%) either transferred care or were lost to 
follow-up (p<0.01), suggesting that HAART with its associated more frequent visit 
schedule improved retention in care, and reflecting that children who were in care for a 
shorter period of time had less opportunity to begin treatment. Figure 1, in addition to 
showing the reduction in population size over time due to death, transfer of care, or loss 
to follow-up, illustrates the timing of HAART initiation. Of the 619 children who 
initiated treatment, 325 (52.5%) did so during the first 30 days of follow-up. 
Estimates of the effect of HAART on mortality are presented in Table 2. Because 
patients with advanced disease are most likely to begin treatment, an unadjusted model 
that did not account for this confounding by indication suggested no effect of HAART on 
mortality, relative to no therapy (HR: 1.38, 95% CI: 0.84, 2.27). An unweighted model 
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that adjusted for baseline confounders only (HR: 0.73, 95% CI: 0.41, 1.31), as well as 
that from an unweighted model that additionally but improperly adjusted for time-varying 
confounders (HR: 0.67, 95% CI: 0.37, 1.21), shifted the estimates in the direction of the 
null but also failed to clearly suggest a protective effect of HAART on survival.. After 
appropriately accounting for time-dependent confounders affected by exposure using 
MSMs, HAART was strongly protective against mortality. The HR from an IPTC-
weighted model was 0.17 (95% CI: 0.05, 0.64), while that from an IPTCV-weighted 
model was 0.25 (95% CI: 0.06, 0.95). The HR from an IPTCV-weighted model before 
the median event time of 2.8 months, 0.29 (95% CI: 0.09, 0.95), was similar to the HR of 
0.18 (95% CI: 0.03, 0.99) after the median (interaction p=0.32). Advanced and severe 
immunodeficiency at baseline, compared to not significant immunodeficiency, were the 
only baseline factors independently associated with mortality in an IPTCV-weighted 
model (HR: 3.16, 95% CI: 1.18, 8.47, and HR: 5.08, 95% CI: 1.49, 17.39, respectively). 
IPTCV-weighted cumulative incidence curves depict the survival benefit of HAART, not 
evident in the unweighted curves that do not adjust for confounding and selection bias 
(Figure 2). 
 
Discussion 
This study, which uniquely uses observational data to estimate the effect of 
HAART on mortality in a pediatric population in a resource-deprived setting, revealed 
that treatment markedly improved the survival of HIV-infected children in Kinshasa, 
DRC. Using a marginal structural model, we estimated that HAART reduced the hazard 
(rate) of mortality during follow-up, relative to no therapy, by 75% (HR: 0.25, 95% CI: 
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0.06, 0.95). Although it was less precise, our result was essentially identical in magnitude 
to the HR of 0.24 (95% CI: 0.11, 0.51) from the only other study in children63 to use a 
method that could overcome barriers to unbiased effect estimation in non-randomized 
data, such as time-dependent confounders affected by exposure. This is particularly 
noteworthy since the earlier study included children enrolled in a multicenter prospective 
cohort study in the United States. 
The equivalence of HRs offers evidence that HAART is as effective in improving 
the survival of HIV-infected children in the DRC, a severely resource-deprived nation 
still recovering from its recent history of poor governance and civil wars,159 as it is in 
resource-privileged settings. This result parallels the consistency of effect observed 
between adults in Europe and the United States61 and South Africa,62 and is important 
because virtually all children receiving HAART globally, due to scale-up of antiretroviral 
provision in low- and middle-income countries, live in resource-poor areas.149 Pediatric 
HIV programs in sub-Saharan Africa, like ours in Kinshasa, often face challenges that 
could adversely affect patient survival, including limited drug options and diagnostic 
capacity, delayed healthcare seeking and poor retention in care, and prevalent 
comorbidities and undernutrition.124 This emphasizes why a homogeneous effect of 
HAART on survival in children could not be assumed across distinct contextual milieus. 
Evidence on the interaction between HAART and nutrition is limited, but it has been 
speculated that micronutrient deficiencies may decrease the effectiveness of antiretroviral 
drugs.160 If true, this might have resulted in effect estimates that were attenuated 
compared to had the children been better nourished overall, although it makes the results 
applicable to similar populations. The higher mortality rate observed during the first 90 
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days of HAART, compared to the rate after 90 days of therapy, was consistent with 
findings in multiple prior pediatric studies.152-156 
The validity of results is contingent upon methodological assumptions, one of 
which is the inclusion of all important confounders. Although HIV RNA was 
infrequently assessed, it is arguable that this factor when available was prognostic for and 
affected by HAART, as well as associated with survival. While not including viral load is 
a limitation that may have introduced some amount of bias into our estimate, failing to 
account for this factor may have only had minimal influence. In the work by Patel et al.,63 
the HR of 0.30 (95% CI: 0.11, 0.82) in the 36% of children with HIV RNA 
measurements was similar to the overall results which were not adjusted for viral load: 
0.24 (95% CI: 0.11, 0.51). Limited availability of second- and third-line drug options, 
and only being able to occasionally measure virological suppression, also meant that 
some children who were recorded as receiving treatment could have actually been failing 
therapy. This may have diluted the estimated effect of HAART if these patients were 
more likely to die. However, because children were frequently evaluated both clinically 
and immunologically, and because adherence was routinely assessed, it is expected that 
inadequate virological control was uncommon. 
As suggested by several recent pediatric studies,152,155,161 it is conceivable that 
some children classified as lost to follow-up actually died, which may have affected both 
the validity and precision of our estimate. If this was more common amongst children not 
receiving HAART, possible because there was less opportunity to discern deaths in these 
children due to their less frequent clinic visits, the strength of effect could have been 
underestimated. Because children not receiving HAART had fewer appointments, their 
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data were correspondingly carried forward to a greater degree, which also may have 
affected results. On a related note, covariate data were quite complete. The variable most 
often missing, because it required laboratory testing and not just simple collection onto 
forms during clinic visits, was CD4 cell percentage. Assuming that children were on 
average halfway to their next scheduled test when follow-up concluded, 83% of the 
expected number of results was available. Data on other time-varying factors were close 
to fully complete. It is important to emphasize that the methods used will not yield a fully 
unbiased measure unless all underlying assumptions are met. If study imperfections 
occurred (e.g., misclassification of HAART status, or the incorrect recording of HIV-
related symptoms or conditions due to the limited capacity in Kinshasa to definitively 
diagnose certain conditions such as cryptococcal meningitis), this is a possibility. 
Strengths of our study include precise ascertainment of dates of HAART initiation 
and death, regular patient follow-up, which mitigated the influence of the carrying 
forward data, and no treatment discontinuation by any active patient, which allowed for 
the intent-to-treat assumption and straightforward effect interpretation. In our setting, 
patients who missed visits were actively tracked, which decreased the possibility that 
children who died were misclassified as lost to follow-up. This is supported by the fact 
that during the first 90 days of HAART, a period when the rate of mortality was high 
(16.4 per 100 person-years; 95% CI: 11.0, 24.5), the rate of loss to follow-up was 
comparatively much lower (3.4 per 100 person-years; 95% CI: 1.4, 8.2). No child had 
ever received therapy prior to participation in our program, which adds to the 
generalizability and relevance of our results because most children initiating HAART 
worldwide are treatment-naïve. Furthermore, given the brief history and limited 
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availability of vertical transmission prevention services in Kinshasa, it is unlikely that 
many children had been previously exposed to prophylactic nevirapine. This means that 
nevirapine-resistant HIV variants162,163 were probably rare, and increases the likelihood 
that the nevirapine-based regimens most children received were effective. Patel et al.63 
sensibly speculate that a stronger HR than 0.24 would have been estimated had their 
population been naïve to treatment rather than experienced. If true, because our HR of 
0.25 was comparable despite arising from treatment-naïve children, it is possible that the 
aforementioned underlying contextual factors may have moved our estimate modestly 
towards the null. 
The large difference between the HRs from the unweighted and weighted models 
indicates that there was considerable time-dependent confounding, and validates the 
analytical approach. The importance of accounting for dynamic visit schedules is 
highlighted by the distinct HRs from the IPTC- and IPTCV-weighted models. 
In summary, HAART had a substantial, beneficial impact on the survival of HIV-
infected children in Kinshasa, DRC. Along with supplementing the limited knowledge 
base on the quantitative effects of pediatric treatment, this study presents the first valid 
estimate to date of the extent by which therapy decreases mortality in a highly relevant 
population of HIV-infected children living in a resource-deprived setting. Our estimate, 
which represents the expected outcome had HAART been evaluated via randomized 
assignment, provides compelling evidence that the accelerating rollout of antiretrovirals 
is a profoundly lifesaving endeavor. Pooled data from pediatric cohorts in less developed 
areas should be used in future research not only to generate more precise effect estimates, 
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but also to focus on the effects of HAART within particular groups such as 
undernourished children, which remain incompletely understood. 
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Table 4. Estimated effect of HAART on mortality among 790 HIV-infected children 
initiating HIV care in Kinshasa, DRC, between December 2004 and May 2010.a 
 
 
a All estimates are derived from pooled logistic models that include time modeled as a 
restricted cubic spline with four knots. Comparing HAART to no HAART, the 
unadjusted mortality rate ratio was 0.54 (95% CI: 0.34, 0.85) while the unadjusted ratio 
of three-year mortality risks was 0.31 (95% CI: 0.23, 0.43). 
 
b CI, confidence interval; HR, hazard ratio; IPTC, inverse-probability-of-treatment-and-
censoring; IPTCV, inverse probability of treatment, censoring, and visit attendance. 
 
 HRb Robust 95% CIb
Unweighted, unadjusted (no confounders) 1.38 0.84, 2.27 
Unweighted, adjusted (baseline confounders only) 0.73 0.41, 1.31 
Unweighted, adjusted (baseline and time-varying confounders) 0.67 0.37, 1.21 
IPTC-weighteda 0.17 0.05, 0.64 
IPTCV-weighteda 0.25 0.06, 0.95 
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Figure 4. Cumulative incidence curves depicting the effect of HAART on survival among 
790 HIV-infected children. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V. 
QUANTIFICATION OF CD4 RESPONSES TO HIGHLY ACTIVE 
ANTIRETROVIRAL THERAPY OVER FIVE YEARS AMONG HIV-INFECTED 
CHILDREN IN KINSHASA, DEMOCRATIC REPUBLIC OF CONGO 
 
Abstract 
 
Background 
In HIV-infected children, the long term effects of highly active antiretroviral 
therapy (HAART) on CD4 responses are incompletely understood. Information from 
resource-deprived areas is particularly scarce, despite the fact that most children with 
HIV live in such settings. 
 
Methods 
We analyzed observational data from HAART-naïve children enrolled between 
December 2004 and May 2010 into an HIV care and treatment program in Kinshasa, 
Democratic Republic of Congo. To estimate the effect of HAART on CD4 percentage 
while accounting for time-dependent confounders affected by prior exposure to HAART, 
a marginal structural linear mean model was used. 
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Results 
790 children contributed 2090 person-years with a median of 31 months of 
follow-up. The median age at the start of follow-up was 5.9 years (interquartile range: 
2.7, 9.8), 405 (51%) were in HIV clinical stage 3 or 4, and 528 (67%) had advanced or 
severe immunodeficiency. During observation, 80 children (10%) died, 76 (10%) were 
lost to follow-up, six (1%) transferred care to another facility, and 619 (78%) initiated 
HAART. Compared to no HAART, the estimated absolute rise in CD4 percentage was 
6.8% (95% CI: 4.7%, 8.9%) after six months of HAART, 8.6% (95% CI: 7.0%, 10.2%) 
after 12 months, and 20.5% (95% CI: 16.1%, 24.9%) after 60 months. CD4 percentage 
gains were slowest but greatest among HAART-treated children who had a baseline CD4 
percentage <15. The cumulative incidence of recovery to “not significant” WHO age-
specific immunodeficiency was lower if HAART was started when immunodeficiency 
was severe rather than mild or advanced. 
 
Conclusions 
HAART increased CD4 percentages among HIV-infected children in a resource-
deprived setting, as previously noted among children in the United States. The more 
gradual and protracted recovery observed in children with lower baseline CD4 
percentages supports the earlier initiation of pediatric therapy. 
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Introduction 
The CD4 cell count and percentage are key markers of HIV disease progression, 
since throughout the course of infection CD4 cells are generally depleted in the absence 
of highly active antiretroviral therapy (HAART).164,165 In children, initiation of HAART 
at low CD4 levels is associated with a reduced likelihood of immune reconstitution114-
116,166 and greater likelihoods of growth failure,166,167 clinical progression,167,168 and 
mortality.102-104,131 HIV treatment guidelines therefore recommend HAART at lower CD4 
cell counts and percentages.157,169 Multiple randomized controlled trials89,170 and 
prospective cohort studies108,171,172 have demonstrated that HAART effectively 
suppresses viral load in children. However, the effect of HAART on immune 
reconstitution in pediatric populations, particularly in resource-deprived settings, remains 
incompletely understood. 
While randomized trials in the United States (U.S.)88 and Europe89 demonstrated 
that children receiving HAART had greater CD4 percentage increases than those 
receiving less potent antiretroviral therapy, the profound survival and clinical progression 
benefits of HAART48,49 restricted subsequent investigations of immunological responses 
to therapy to observational contexts. Prior pediatric studies have generally been of short 
duration91,102-104,107,108,116,117,166,167,172-179 with limited available sample 
sizes91,103,104,107,108,115,117,166,167,173-175,177-183 and were unable to contrast the effect of 
HAART in comparison to no HAART. One study estimated the effect of HAART versus 
no HAART on CD4 percentage, finding that the mean CD4 percentage of 1236 U.S. 
children rose by 2.3% after one year of HAART compared to no HAART, with the 
difference increasing to 4.4% by five years.95 Of the studies in low resource areas,102-
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104,107,108,166,172,173,175-177,184 just two27,41 appraised CD4 responses at more than two years 
after HAART initiation with none quantifying the effect of HAART on immune 
reconstitution relative to no HAART. 
Global access to HAART is expanding,30 including to the over 90%1 of children 
living with HIV infection in areas of the world where poverty and undernutrition are 
common and may affect HAART outcomes.124,185 Since HAART reduces morbidity and 
mortality among HIV-infected children in resource-deprived settings,133,186,187 these 
children may be on HAART for decades. Hence understanding immune reconstitution 
over longer periods of time in this population is essential. Further work on responses to 
HAART in this group may also inform the optimal timing of HAART initiation in 
children greater than two years of age.123,157,188,189 Therefore, we estimated the effect of 
HAART on mean CD4 percentage in an observational clinical cohort of HIV-infected 
children in the Democratic Republic of Congo (DRC), using marginal structural models 
(MSMs) to account for confounders affected by prior exposure while adjusting for time-
dependent confounding by indication. 
 
Methods 
 
Study Population, Measurements, and Follow-up 
We used data from a comprehensive, family-centered HIV care and treatment 
program at two sites in Kinshasa, DRC: Bomoi Healthcare Center and Kalembe Lembe 
Pediatric Hospital.133,186 The study population was restricted to HAART-naïve children 
less than 18 years of age at baseline with HIV infection confirmed by serology if at least 
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18 months of age and by DNA PCR or HIV viral load otherwise. If a child’s CD4 
percentage was obtained at time of program enrollment, baseline was defined as the date 
of HIV care initiation (between December 2004 and May 2010); otherwise, baseline was 
defined as the date of first CD4 percentage result. As in previous studies,63,93 this allowed 
children to be included despite missing baseline data. Follow-up continued until either 
the date of death or the clinic visit preceding loss to follow-up, transfer of care, or August 
2010. Children were classified as lost to follow-up if they withdrew from care or were not 
located by three tracking attempts after a missed visit. All children who initiated HAART 
contributed no HAART person-time prior to HAART initiation. 
Laboratory monitoring, diagnosis and treatment of opportunistic infections, and 
prescription of cotrimoxazole prophylaxis and HAART were based on national135 and 
World Health Organization (WHO)105,122,134,157 guidelines. The first-line HAART 
regimen consisted of of zidovudine or stavudine, lamivudine, and nevirapine or efavirenz 
and could be initiated at any visit after enrollment. Infants less than two years of age were 
not always started on therapy immediately, as recommended by WHO in 2009,157 
because virological diagnostics were only intermittently available. Physicians 
documented clinical data using standardized forms during routine visits (scheduled 
monthly for children receiving HAART and quarterly for children not receiving HAART) 
and unscheduled visits (for children needing acute care). If a child died, program 
personnel collected the date and suspected cause of death. CD4 cell count and percentage 
were assessed biannually at the DRC National AIDS Reference Laboratory. HIV viral 
load was only occasionally available. 
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Parental informed consent for the HIV care program was obtained for all children, 
with minors at least 12 years of age additionally providing their assent. The University of 
North Carolina at Chapel Hill Institutional Review Board and the Ethics Committee of 
the Kinshasa School of Public Health approved the study. 
 
Statistical Analysis 
Estimation of the total effect of HAART on change in mean CD4 percentage at 
time t, the primary aim of analysis, entails adjustment for factors that are common causes, 
or confounders, of both exposure and outcome. Whereas some confounders are measured 
at baseline only, others, known as time-varying confounders affected by prior exposure, 
are measured throughout follow-up and are causal intermediates between HAART and 
CD4 percentage at time t while concurrently common causes of subsequent HAART 
status and CD4 percentage at time t. Specifying time-varying confounders affected by 
prior exposure, for example CD4 percentage at times prior to t, as time-varying 
covariates in a standard regression model will fail to yield the total effect of HAART on 
change in mean CD4 percentage at time t because the effects of HAART are mediated in 
part through the time-varying factors. Therefore, to appropriately estimate the 
immunological effect of HAART in the presence of such factors, we used inverse 
probability weighting. 
Our dataset was configured into a one row per person-day structure, with missing 
covariate data carried forward from last measurement. We used covariate histories and 
six logistic regression models to predict child and time-specific probabilities of treatment, 
censoring, and visit attendance, which were then multiplied to calculate composite 
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stabilized inverse probability weights. Specifically, time and baseline confounders were 
predictors in the models for the treatment weight numerator and denominator, with time-
varying confounders affected by prior exposure also included in the latter. The censoring 
weight numerator and denominator models, as well as those for the visit attendance 
weight numerator and denominator, were identical to the treatment weight models except 
for the additional inclusion of time-varying HAART as a predictor in the two censoring 
models, and both time-varying HAART and time since last visit in the two visit 
attendance models. The combined weights were then applied in a linear regression model 
with cumulative HAART exposure and baseline confounders as independent variables 
and CD4 percentage as the outcome, using only observations with a measured CD4 
percentage result, to estimate the parameters of a linear repeated measures MSM. To 
account for within-subject correlation induced by weighting and resulting from repeated 
CD4 percentage measurements in individuals, and to yield 95% confidence intervals 
(CIs) based on robust variance, the model was fitted using generalized estimating 
equations with an independent working covariance matrix. If children received 
uninterrupted HAART during follow-up, plausible in our program because physicians 
routinely assessed adherence and never discontinued treatment for active patients, and 
assuming correct model specification along with no unmeasured confounding or 
informative censoring, the MSM yields the difference in mean CD4 percentage had 
children started HAART immediately compared to had they never started HAART during 
follow-up. 
A posited directed acyclic graph140 and previous studies informed confounder 
selection. Age, gender, and WHO HIV clinical stage and severity of immunodeficiency 
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were baseline confounders, while time-varying confounders affected by prior exposure 
were cotrimoxazole prophylaxis, HIV-related symptoms or conditions, and CD4 
percentage. Age and CD4 levels were used to calculate age-specific severity of 
immunodeficiency (not significant, mild, advanced, or severe), based on WHO 
guidelines.105 For all children, including those for whom follow-up started at first CD4 
result rather than HIV care initiation, HIV clinical stage (1-4) was that at enrollment 
because it was assessed only at first visit. A child had HIV-related symptoms or 
conditions if diagnosed with one or more of the following: Kaposi’s sarcoma, oral or 
esophageal candidiasis, severe weight loss, tuberculosis, fever or diarrhea of one month 
or more, lymphocytic interstitial or Pneumocystis jirovecii pneumonia, chronic herpes 
simplex, oral hairy leukoplakia, cryptococcal meningitis, toxoplasma or HIV 
encephalopathy, or HIV-associated nephropathy. Gender, cotrimoxazole, and symptoms 
or conditions were coded dichotomously, as was HAART in logistic models. In linear 
models, cumulative HAART exposure was coded into indicators for six month 
categories, that is, no HAART, >0 to 6 months, >6 to 12 months, and so on through a 
maximum of 66 months. Age and time were modeled as restricted cubic splines with four 
knots at the 5th, 35th, 65th and 95th percentiles, as was CD4 percentage when a time-
varying confounder affected by prior exposure. CD4 percentage, which was examined 
because it is a more stable metric than absolute CD4 count in children,190 was expressed 
as a whole number when an outcome in linear models. 
Results from unadjusted as well as adjusted but unweighted linear repeated 
measures models were examined for comparison to elucidate reductions in bias by use of 
weighted models. To estimate the effect of HAART on CD4 percentage by baseline 
 80 
 
categories (CD4 percentage <15%, 15%–24%, and ≥25%), models were fitted within 
those strata. We used the log-rank test after constructing Kaplan-Meier plots and Cox 
proportional hazards regression to assess whether time to reaching “not significant” 
WHO age-specific immunodeficiency differed by degree of immunodeficiency (mild, 
advanced, severe) at HAART initiation. The proportionality of hazards was verified by 
visual inspection of log-negative-log survival estimates. All analyses, including a 
macro146 to generate cumulative incidence curves191 to visually depict time to 
immunological recovery, were completed in SAS version 9.2 (SAS Institute, Cary, NC). 
 
Results 
Characteristics of the 790 children at the start of and during follow-up are 
presented in Table 1. At baseline, the median age was 5.9 years (interquartile range 
[IQR]: 2.7, 9.8) and more than half (405, 51.3%) had clinically evident stage 3 or 4 HIV 
disease. As the median CD4 percentage was 15 (IQR: 9, 22), immunodeficiency was 
either advanced (76, 9.6%) or severe (452, 57.2%) in most patients. Cotrimoxazole was 
initiated by almost all children (726, 91.9%) at first visit. 
During the 2089.8 person-years accrued, the median duration of follow-up was 
31.2 months (IQR: 10.3, 53.6), and the median number of clinic visits was 30 (IQR: 11, 
57). The number and proportion of patients active in HIV care for at least 12, 24, 36, 48, 
and 60 months were 573 (72.5%), 440 (55.7%), 352 (44.6%), 279 (35.3%), and 127 
(16.1%), respectively. Eighty children (10.1%) died, 76 (9.6%) were lost to follow-up, 
and six (0.8%) transferred to another care facility. HAART was started by 619 children 
(78.4%) at a median of 4.0 months (IQR: 2.2, 15.3) after baseline. At initiation, the 
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median CD4 percentage was 12 (IQR: 7, 18) and 454 children (73.3%) were severely 
immunosuppressed. Durations of HAART during follow-up and the number of CD4 
percentage measurements during each of the six month periods are depicted in Figure 5. 
HAART was received by 167 children (27.0%) for >0-12 months, 177 (28.6%) for >12-
36 months, and 275 (44.4%) for >36 months. Those receiving HAART, 110 (17.8%) of 
whom changed regimens because of treatment failure or an adverse event, were followed 
for a median of 31.3 months (IQR: 11.4, 52.0) and contributed 1620.9 person-years 
(77.6% of the total) while on HAART. Of the 3137 total CD4 percentage measurements, 
2485 (79.2%) were obtained during receipt of HAART. 
According to the MSM, HAART resulted in a 6.8% (95% CI: 4.7%, 8.9%) 
absolute rise in mean CD4 percentage in the first six months and a 8.6% (95% CI: 7.0%, 
10.2%) gain at 12 months, relative to no HAART (Table 2, model 4; Figure 6, panel A). 
The rate of increase was less in subsequent months and years. Not properly accounting 
for time-varying confounders affected by prior exposure yielded attenuated effects (Table 
2, models 1-3). For comparison to the appropriately adjusted model-based results, we 
also plotted the observed, unadjusted CD4 percentage evolutions for children receiving 
HAART and children not receiving HAART (Figure 6, panel B). 
The effect of HAART on CD4 percentage differed by category of CD4 percentage 
at baseline (Figure 7). In children with a baseline CD4 percentage ≥ 25%, CD4 
percentage rose by almost 10% (95% CI: 7.4%, 12.4%) in the first 12 months, to a mean 
of 40%, and stabilized. In children with a baseline CD4 percentage of 15%–24%, CD4 
percentage increased rapidly in the first 12 months, to a mean of 29%, with more gradual 
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increases thereafter. Gains were slower in children with a baseline CD4 percentage 
<15%. 
Only 83 of 619 children (13.4%) had “not significant” WHO age-specific 
immunodeficiency at time of HAART initiation. There was a reduced hazard of recovery 
to “not significant” immunodeficiency (unadjusted hazard ratio: 0.62; 95% CI: 0.40, 
0.96) and a corresponding longer time to recovery (log-rank p=0.03) if HAART was 
initiated when immunodeficiency was severe rather than mild or advanced. In the 82 
children who initiated HAART with either mild or advanced immunodeficiency, the 
cumulative incidences of recovery to “not significant” immunodeficiency at 12, 24, and 
36 months were respectively 28.5%, 36.3%, and 42.7%, while the proportions in the 454 
children who started HAART with severe immunodeficiency were 17.5% by 12 months, 
26.0% by 24 months, 27.7% by 36 months, and 29.9% by 48 months (Figure 8). 
 
Discussion 
HAART markedly increased the mean CD4 percentage in a cohort of HIV-
infected children in Kinshasa, DRC compared to no HAART, by 8.6% (absolute) at 12 
months and 20.5% at 60 months of HAART. Our study provides the first estimate of the 
effect of HAART on CD4 percentage relative to no HAART among antiretroviral-naïve 
children in a resource-deprived setting and just the second estimate of this informative 
contrast overall.95 This was achieved by using inverse probability weighting to account 
for evident biases. Additionally, our study is one of the few providing evidence of 
sustained CD4 percentage improvements following HAART initiation in children.63,186 
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Our findings that HAART increased CD4 percentages in children over the short 
and long term, both overall and within baseline CD4 percentage categories, were 
generally concordant with those from the methodologically similar U.S. study.95 That 
study reported lesser gains throughout follow-up (e.g., 2.3% and 4.4% at 12 and 60 
months, in contrast to 8.6% and 20.5%). This could be due to the large difference in the 
baseline CD4 percentage distributions of the study populations, as the median baseline 
CD4 percentage was approximately 25% in the U.S. cohort compared to 15% in the 
Kinshasa cohort. A higher baseline CD4 percentage results in lower potentials for gains. 
The difference was also present within strata, and may contribute to the greater and more 
rapid change we noted among children with a baseline CD4 percentage ≥25%. 
Among children with a baseline CD4 percentage <15%, the CD4 percentage 
increases at 12 and 24 months of HAART (4.0% and 10.0%) were close to those noted in 
the U.S. study (4.4% and 8.0%). In these children, the mean CD4 percentage recovered 
by 42 months to “normal” levels (>25%).95,168,176 While this indicates that recovery is 
possible for children initiating HAART with advanced immunodeficiency, CD4 
percentages remained below 20% even after 24 months. The prolonged period of 
immunodeficiency likely contributes to prolonged morbidity and mortality during 
HAART. The decreased probability of immunological treatment success following 
initiation at low CD4 levels revealed in our and prior studies,95,114-116,166 as well as high 
mortality rates in children initiating HAART at low CD4 percentages,102-104,131 provide 
compelling evidence that pediatric HAART should not be delayed until CD4 percentages 
drop below 15%. The newly revised WHO guidelines are in accordance with this 
evidence.157 
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Not being able to include HIV viral load as a confounder was a limitation, as was 
the lack of diagnostic capacity in Kinshasa to identify all HIV-related symptoms and 
conditions. The appropriateness of the methodological approach, including accounting 
for the dynamic visit schedule and its potential to influence result validity,143 was 
supported by the dissimilar results from weighted and standard unweighted models. 
Exposure misclassification was minimized through accurate recordkeeping of initiation 
dates and frequent monitoring of adherence. However, because virological monitoring 
was infrequent and drug options were limited in our setting, the possibility exists that 
some children recorded as receiving HAART were actually failing therapy, which may 
have biased our estimates downward. We also examined immunological recovery by 
severity of immunodeficiency and not just CD4 percentage categories. 
Our results build upon prior evidence showing the positive immunological impact 
of pediatric HAART across CD4 levels and supporting therapy initiation prior to immune 
system degradation. By contributing unique, relevant information on long term responses 
in a resource-deprived setting, this study widens the breadth of understanding on a 
relationship that is central to the morbidity and mortality outcomes of HIV-infected 
children. Future efforts should focus on pooling data from similar cohorts in order to 
more precisely estimate effects within immunological subgroups and even longer after 
HAART begins.
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Table 5. Characteristics of 790 children initiating HIV care between December 2004 and 
May 2010 in Kinshasa, DRC. 
 
a Baseline was shifted from enrollment to date of first CD4 percentage result for 41 of 
790 children (5.2%). For these 41 children, the median number of months from 
enrollment to first CD4 percentage was 2.3 (IQR: 1.1, 5.3). 
 
b IQR, interquartile range; WHO, World Health Organization. 
BASELINE a  
Median age, years (IQRb) 5.9 (2.7, 9.8) 
Age [n (%)] 
          <1 
          1–4 
          5–9 
          10–17 
63 (8.0) 
277 (35.1) 
265 (33.5) 
185 (23.4) 
Female sex [n (%)] 415 (52.5) 
WHOb HIV clinical stage [n (%)] 
          1 
          2 
          3 
          4 
153 (19.4) 
232 (29.4) 
369 (46.7) 
36 (4.6) 
Median CD4 percentage (IQRb) 15 (9, 22) 
WHOb age-specific severity of immunodeficiency [n (%)] 
          Not significant 
          Mild 
          Advanced 
          Severe 
174 (22.0) 
88 (11.1) 
76 (9.6) 
452 (57.2) 
Started cotrimoxazole at first visit [n (%)] 726 (91.9) 
FOLLOW-UP (ALL CHILDREN)  
Total person-years accrued 2089.8 
Median months of follow-up (IQRb) 31.2 (10.3, 53.6) 
Median number of program visits (IQRb) 30 (11, 57) 
Died [n (%)] 80 (10.1) 
Lost to follow-up [n (%)] 76 (9.6) 
Transferred care [n (%)] 6 (0.8) 
Initiated HAART 619 (78.4) 
Number of CD4 percentage results 3137 
FOLLOW-UP (CHILDREN INITIATING HAART)  
Median weeks of follow-up prior to HAART initiation 4.0 (2.2, 15.3) 
Severe immunodeficiency at HAART initiation [n (%)] 454 (73.3) 
Median CD4 percentage at HAART initiation (IQRb) 12 (7, 18) 
HAART person-years accrued 1620.9 
Median months on HAART (IQRb) 31.3 (11.4, 52.0) 
Switched HAART regimen [n (%)] 110 (17.8) 
Number of CD4 percentage results during HAART 2488 
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Figure 7. Estimated effect of HAART on CD4 percentage, by category of CD4 
percentage at baseline, 790 children initiating HIV care between December 2004 and 
May 2010 in Kinshasa, DRC.a  
 91 
 
a Estimates are from repeated measures linear models, fit with generalized estimating 
equations, that include time modeled as a restricted cubic spline with four knots. As there 
were no discernable upward or downward trends in CD4 percentage over time among 
children not receiving HAART when spline terms were included as predictors in the 
stratum-specific models, it is assumed that the cumulative HAART exposure parameters 
represent change from baseline. Error bars represent 95% confidence intervals.
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VI. 
DISCUSSION 
 
Summary of Findings 
Data from an observational cohort of HIV-infected children participating in a care 
and treatment program in Kinshasa, DRC were used to address three specific aims. The 
first two aims focused on estimation of the effects of HAART. The outcome examined in 
the first aim was survival, while the goal of the second aim was to quantify the effect of 
HAART on CD4 percentage, a marker of immunological progression, both overall and by 
baseline category of CD4 percentage. The third aim was to determine whether the degree 
of immunodeficiency upon commencement of HAART was associated with eventual 
recovery to “not significant” WHO age-specific immunodeficiency. 
The effects of HAART on survival and CD4 percentage among children in the 
resource-deprived setting of Kinshasa were similar to those previously noted among 
children in the United States.  Contrasting HAART to no HAART, the HR for mortality 
was 0.25 (95% CI: 0.06, 0.95), and the estimated absolute CD4 percentage improvement 
was 6.8% (95% CI: 4.7%, 8.9%), 8.6% (95% CI: 7.0%, 10.2%), and 20.5% (95% CI: 
16.1%, 24.9%) after six, 12, and 60 months of HAART, respectively. Across baseline 
CD4 percentage categories, HAART led to short and long term immunological gains, 
although the rise was slower among children who had a baseline CD4 percentage <15. If 
HAART was started when immunodeficiency was severe rather than mild or advanced, 
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there was a lower cumulative incidence of recovery to “not significant” WHO age-
specific immunodeficiency at 12, 24, and 36 months after HAART initiation. 
 
Contributions of Findings 
There are several ways that this work extends the scope of the literature on the 
effects of HAART on HIV disease progression. The study is unique not only because of 
its pediatric focus; it is also highly and increasingly relevant because of its focus on 
children who, like most individuals receiving HAART globally, are treated in a resource-
deprived setting. The study examined survival as well as short and longer term 
immunological outcomes, and improved upon prior research by using an antiretroviral-
naïve rather than a fully or partially non-HAART comparison group. Given that answers 
to questions concerning the effects of HAART in children are ethically unobtainable via 
randomized trial, the specific aims were assessed by utilizing observational data in 
concert with appropriate epidemiological methods such as MSMs estimated by inverse 
probability weighted regression. 
The provision of HAART in resource-deprived environments is fraught by 
distinct challenges that may impact outcomes. This study, which was timely and pertinent 
because HAART rollout in the developing world will continue to increase in coming 
years if current trends continue,30 helped to mitigate context-specific substantive gaps. 
For instance, given that findings emerged from a program with limited diagnostic and 
laboratory capacity that serves a population faced by prevalent comorbidities and 
undernutrition, the research informs expectations for the effects of HAART on survival 
and CD4 percentage in such environments. In doing so, it may help to maintain the 
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momentum for the provision of pediatric HIV care and treatment in areas where it is most 
urgently needed. For example, the general finding that the effectiveness of HAART in 
Kinshasa, according to the metrics examined, was similar to that in more developed 
settings serves as empirical evidence to support the scale-up of programs in areas that are, 
relatively speaking, less resourced. This is particularly important given the current global 
economic downturn and the 2010 UNAIDS report1 which states that HIV has “halted” 
and “begun to reverse,” which together combine as an unfortunate pretext for the 
rationalization of decreased financial commitment to fight the epidemic. The UNAIDS 
report1 notes that “growth in investment for the AIDS response has flattened for the first 
time,” and a report published by Médecins Sans Frontières (MSF) entitled “Punishing 
Success: Early Signs of a Retreat from Commitment to HIV Care and Treatment” warns 
that the Global Fund to Fight AIDS, Tuberculosis and Malaria funded 35% fewer 
proposals in 2009 than in 2008 and that PEPFAR has capped spending despite increasing 
outlays during the past five years.192 An HIV/AIDS policy adviser for MSF cites 
increasing stock-outs of antiretroviral drugs and a “significant gap” between the 
calculated needs of countries over the next decade and pledged donor contributions.193 
While no single factor can stem the tide of decreasing financial support for anti-
HIV initiatives, evidence that HAART can be effective in settings where it is most widely 
required, like that from this study, plays an essential beneficial role. This work, due to the 
simple fact it included nearly 1,000 children who were not receiving care before their 
enrollment into the Kinshasa program, is illustrative of the reality that profound needs 
endure even while HIV incidence and prevalence is stabilizing or declining in many 
areas.1 In the DRC alone, there are an estimated 60,000 women each year needing of 
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prophylactic antiretroviral drugs to decrease the risk of vertical transmission, though 
access remains extremely limited.194 Worldwide, the annual number is nearly 1.4 million, 
with only half of women having access to services.30 Approximately three in four of the 
1.3 million children in low-and middle income countries who need HAART are not 
receiving it.30 For the foreseeable future, pediatric HIV will remain a pressing public 
health issue that demands a sustained and systematic response. 
This study meaningfully contributes to the ongoing debate on when pediatric 
HAART should be started. It was revealed that the immunological response to HAART 
was unequal across baseline CD4 percentage categories, with recovery more gradual in 
the lowest CD4 percentage group, and that greater immunodeficiency at HAART 
initiation was associated with impaired recuperation to the “not significant” level. These 
findings suggest that HAART should be started earlier rather than later, and could be 
used to inform antiretroviral guidelines. Thus, they could have downstream effects on 
clinical practice and the delivery of care, in addition to policy. 
There are several related points worth noting. First, it is possible to investigate the 
question via other observational means such as the application of methods to mimic trials 
of immediate versus deferred HAART, as previously described. However, it is still 
informative, as emphasized by the multitude of cited studies that have done so, to 
examine whether experiences differ across baseline CD4 strata. Second, this study 
bolsters a knowledge base in children that is narrow, particularly in resource-deprived 
settings. The WHO pediatric antiretroviral guidelines105,157 are based on observational 
data from resource-privileged contexts that examined how CD4 levels influenced survival 
outcomes among children who were untreated or receiving AZT monotherapy,195,196 and 
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call for research in resource-deprived settings to evaluate the appropriateness of their 
thresholds for starting HAART. This study responds to that call, and augments the 
currently available evidence which is described as “very low quality” by WHO. Third, 
longer term immunological recovery was examined, an aspect that is crucial because this 
endpoint, in addition to clinical outcomes, is an important marker of the success of 
HAART. Simply stated, this work helps to widen the breadth of what is known about an 
issue that remains only partially understood. 
These findings may also contribute to future cost-effectiveness and mathematical 
modeling analyses. The authors of a recent study of the causal effect of HAART on 
mortality in adults61 express that it “would be highly desirable to have a reliable estimate 
of the effect of cART on the overall survival for public health planning and to inform 
HIV modeling and cost/effectiveness calculations.” The estimates from Kinshasa could 
be used for these purposes as well. For example, the survival results have utility in years 
of life lost calculations, and if the finding that it takes longer for children with lower 
baseline CD4 percentages to attain “safe” levels is assumed to be true, the risks of death 
and clinical progression while immunodeficiency is high could be weighed against the 
risk of adverse events arising from receiving HAART for a period of many years. 
 
Strengths and limitations 
This study, like any other, featured various strengths and limitations. One 
limitation was that data on HIV viral load, a factor that fits the definition of a time-
dependent confounder affected by exposure, were extremely sparse as a result of 
logistical and infrastructural constraints in the DRC, and therefore could not be 
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incorporated into the analysis. While some studies had the luxury of including this 
variable,55,58-61,93,94 many were unable to do so because they used data from an era54,63,92,95 
or setting62,133 where this biomarker was not measured. While it is acknowledged that the 
effects of HAART on survival and CD4 percentage may have been underestimated if the 
few available virological results were used to inform HAART initiation decisions, it is 
encouraging that the methodologically strongest previous study of children juxtaposed 
their overall findings with those from a sub-analysis that accounted for viral loads in the 
36% of the study population that had virological data, and found that the effect of 
HAART on survival was virtually unchanged.63 
On a related note, it can also be argued that clinical status (e.g., WHO HIV 
clinical stage) is a time-dependent confounder affected by exposure. Similar to viral load, 
some studies account for this factor,55,59,63,94,95 while most others (including some that 
account for viral load) do not.54,60-62,92,93,133 In the Kinshasa care and treatment program, 
WHO HIV clinical stage is assessed only at enrollment. While it theoretically would have 
been possible to assign a clinical status value to every visit by abstracting and coding 
physicians’ past observations, this was not practically feasible given that more than 
20,000 records would have needed to be reviewed. 
It is also worth putting into perspective the amount of person-time that this study 
featured. While most of the highlighted MSM analyses included more person-time than 
did this study, it is worth noting that several studies involved a comparable amount of 
collective follow-up,58,132 and several others were published with considerably 
less.60,94,133 The only other study from a sub-Saharan African setting, of adults, included 
many more individuals (14,267) than this cohort, but the median follow-up duration was 
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only four months.62 In examining longer term effects of HAART in a resource-deprived 
context, this study was unique, and also featured the first investigation in children. 
Other related studies have lacked exact information on when HAART was 
initiated (leading to assumptions on actual start dates, and possible biases), featured 
infrequent follow-up (leading to speculation that data may be misclassified), and included 
individuals who started HAART but later discontinued it (leading to unclear 
interpretation of effect estimates). This study improved upon these shortcomings. First, 
children visited the program no less than quarterly; in fact, most visited monthly. These 
frequent visits mitigated the downsides of the “carry forward” approach to missing data. 
Specifically, having subsequent observations that were temporally closer made it easier to 
tell if a particular value for a given variable, for example HIV-related symptoms or 
conditions, was coded incorrectly and required correction. Second, the precise dates of 
HAART initiation were available. Third, barring any undisclosed lack of adherence as 
counseling is provided at each visit, children remained on HAART once initiated.  
The data used in this study were remarkably complete. While the carry forward 
approach did obviate any gaps in time-dependent covariates, there was very little such 
filling of missing data collection during follow-up. Data were almost invariably complete 
on variables including WHO HIV clinical stage, age, and gender, which was vital 
because complete baseline covariate data was a universal inclusion criterion, as noted in 
the Study population section. To account for the fact that a small percentage of children 
were not immunologically assessed at enrollment, baseline was reassigned to the first 
CD4 percentage result when necessary, as in prior related studies.55,63,93,95,132  
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It should be noted that some other similar studies adjusted for additional baseline 
and time-dependent covariates, such as total white and red blood cell counts and 
hemoglobin, platelet, and CD8 cell levels. If this analysis were to have included these 
factors, which may not have been prognostic for HAART in this setting, some individuals 
would have been excluded due to unavailability of baseline data. For example, as 
approximately 10% of enrolled children to date do not have an initial hemoglobin 
measurement, the decision to include hemoglobin would have reduced the proposed study 
population by a corresponding degree unless missing baseline data were predicted via 
imputation or assumed to be equivalent to a subsequent measurement, two approaches 
that are imperfect. No factors highly suspected as confounders were excluded from 
analysis, even if the amount of missing data at baseline was considerable. 
 Although featuring many excellent qualities, as described, the data were 
insufficiently rich to address all possible questions about the effects of HAART on 
survival and clinical and immunological progression. For instance, the size of the study 
population and the total amount of person-time was not enough to examine the effects of 
HAART on survival by levels of baseline immunodeficiency or undernutrition, or the 
effects of HAART on immunological outcomes within categories of baseline CD4 
percentage and undernutrition. Investigating a clinical progression outcome such as AIDS 
was not possible not only because a non-negligible proportion of children had an 
advanced disease state at enrollment, and hence would have been excluded from such an 
analysis, but also because the diagnostic capacity in the DRC is less than that in resource-
privileged settings. This means that all qualifying conditions in the AIDS case 
definition19 (e.g., cytomegalovirus retinitis, chronic intestinal isosporiasis) could not have 
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been identified, meaning that the study would have been adversely affected by at least 
some degree of outcome misclassification. Additionally, it would have been necessary to 
complete a comprehensive review of physicians’ notes for tens of thousands of visits in 
order to conclude with a high degree of confidence whether a patient had AIDS, a process 
that is substantially more involved than determining if a checkbox for at least one HIV-
related symptom or condition was marked. 
 
Future Research Directions 
 The above limitations inspire directions for future research, which will be possible 
if data from pediatric HIV care and treatment programs are pooled, as has been done with 
adult data from the United States and Europe,61 or if a program accrues sufficient 
individuals and person-time. Repeating the same analyses using such a dataset would 
improve the precision of all estimates and would allow for even longer term assessment 
of the immunological effects of HAART, both important goals in their own right. Data 
pooled from other programs, however, would also allow for the investigation of new 
questions: specifically, those that cannot be pursued with the Kinshasa data alone. These 
include the effects of HAART on adverse events, on clinical progression, on survival by 
baseline immunodeficiency and by baseline undernutrition, and on immunological 
progression by both baseline CD4 percentage and undernutrition. 
Undernutrition has been repeatedly alluded to as an important factor in resource-
deprived settings, and as a target for future research in terms of its connection with the 
effects of HAART on survival and clinical and immunological progression. The influence 
of undernutrition on those associations is only partially understood, even though it is both 
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common among HIV-infected children and well known to be a determinant of health 
outcomes. A review of the interplay between HIV and nutrition is thus warranted. 
There is little doubt that the connection between nutritional status and HIV is 
synergistic. The basis for this claim is twofold. First, the course of HIV infection – that is, 
loss of cell-mediated immunity followed by the development of opportunistic infections – 
leads to undernutrition, a reality reflected by the classification of wasting syndrome as an 
AIDS-defining condition.19 As immunodeficiency worsens, HIV patients often 
experience chronic diarrhea caused by opportunistic pathogens including Cryptosporidum 
parvum, Mycobacterium avium complex, and cytomegalovirus,197,198 which results in 
weight loss,199,200 malabsorption of sugar and fats,201-203 and small bowel morphology 
abnormalities that exacerbate malabsorption.204 Couple these effects with reduced oral 
intake during acute episodes of opportunistic disease205,206 in addition to an increased 
metabolic rate205,207 and greater protein and micronutrient needs208 during infection, and it 
is clear how HIV can lead to undernutrition. Second, even in the absence of the virus, 
undernutrition results in several of the same clinical and immunological consequences as 
HIV. On its own, undernutrition is a cause of mortality209,210 and leads to impairments in 
immune function.211,212 Considering these facts collectively, there is a substantive 
foundation for nutritional status impacting survival as well as clinical and immunological 
progression within the context of HIV infection, and these relationships have been 
studied. 
There is a growing body of evidence on the associations between nutritional status 
and outcomes in HIV-infected individuals. The endpoint that has been examined in 
relation to nutritional status in HIV infection is survival, and this connection is better 
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understood than the association between nutritional status and immunological outcomes. 
Several studies focused on patients not receiving ART. In an unadjusted analysis of 514 
untreated Zambian children less than 15 years of age who were followed for an average 
of two years, the hazard of death increased if the baseline weight-for-age Z-score (WAZ), 
a marker of nutritional status,213 was lower (i.e., was indicative of more severe 
undernutrition).214 In multivariable analysis, for every one standard deviation increase in 
WAZ, the hazard of death decreased by approximately 20% (HR: 0.83; 95% CI: 0.76, 
0.91). Among 48 untreated South African infants, those who died during follow-up 
(mean, 28.5 months) were more undernourished beginning at three months of age than 
those who survived.215 A 1989 chart review of 32 deceased AIDS patients showed that 
the degree of undernutrition was more severe closer to the time of death;216 another study 
in the pre-antiretroviral era followed 39 AIDS patients for a mean of 212 days and found 
that survival was greatly prolonged if the body cell mass was greater than 30% of body 
weight.217 A meta-analysis of 2,510 untreated children from 10 cohorts in resource-
deprived settings revealed that low WAZ was predictive of death over 12 months of 
follow-up, across strata of immunodeficiency.218 
The influence of nutritional status on survival in the context of HAART has also 
been evaluated. One study followed 394 treated Singaporean adults, 35% of whom 
received HAART, for a median of 2.4 years – in multivariable analysis, those with a body 
mass index (BMI) indicative of moderate or severe undernutrition (less than 17 kg/m2) at 
time of HAART initiation, relative to no undernutrition (BMI above 18.5 kg/m2), were at 
a higher hazard of death (HR: 2.19; 95% CI: 1.29, 3.73).219 This finding was corroborated 
in an analysis of 1,507 Malawian adults, which revealed that individuals were more likely 
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to die during the first three months of HAART if they were more severely 
undernourished at time of HAART initiation.220 Compared to no undernutrition, the 
adjusted OR of death given mild undernutrition (BMI between 17 and 18.5 kg/m2) was 
2.1 (95% CI: 1.2, 3.8), with adjusted ORs of 2.4 (95% CI: 1.7, 6.3) given moderate 
undernutrition (BMI between 16 and 17 kg/m2) and 6.0 (95% CI: 4.6, 12.7) given severe 
undernutrition (BMI less than 16 kg/m2). Results were similar in a study that followed 
320 HAART-initiating Tanzanians aged 15 years or more for a median of 11 months – 
relative to no undernutrition, the hazard of death was elevated given severe 
undernutrition at HAART initiation (HR: 2.12; 95% CI: 1.06, 4.24).221 Compared to 
normal BMI, low BMI at HAART initiation has been independently linked to mortality in 
the first six months of HAART among adults in Malawi (HR: 2.92; 95% CI: 2.04, 
4.17)222 and Zambia (HR: 2.4; 95% CI: 1.8, 3.2).97 Initial body weight in the lowest 
gender-specific quartile was associated with death among 910 Haitians aged 13 years or 
more who started HAART and were followed for a median of 13 months (HR: 3.3; 95% 
CI: 2.9, 3.7).223 
In children, a previously described observational study to compare HAART with 
less potent combination ART suggested that for each one standard deviation increase in 
WAZ at time of initiation, the hazard of death was reduced by approximately 20% (HR: 
0.82; 95% CI: 0.61, 1.10).75 Severe wasting was associated with mortality during the first 
three months of HAART in 439 Malawian children,224 and each one standard deviation 
increase in baseline WAZ decreased the hazard of death during the first year of HAART 
by over half among 299 children in the DRC (HR: 0.39; 95% CI: 0.26, 0.57).125 An 
increasing hazard of death across four levels of decreasing baseline WAZ was noted 
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among 2,398 Zambian children who started HAART and were followed for a median of 
378 days,102 and in 236 Haitian children initiating HAART who were followed for a 
median of 20 months, a baseline WAZ more than three standard deviations below the 
median, compared to less undernourishment, was associated with an increased hazard of 
death (HR: 2.07; 95% CI: 1.39, 3.10).103 
Evidence on the influence of nutritional status on immunological outcomes is 
more sparse. One study that examined the impact of nutritional status on survival also 
evaluated changes in CD4 counts at six and 12 months after initiation of HAART or less 
potent ART, and found that baseline BMI was not associated with immunological 
response.219 This result was echoed in a study of 1,458 children in the United Kingdom, 
Ireland, and Uganda in which WAZ at time of HAART initiation was unrelated to a CD4 
percentage change of at least 10% six months later.225 However, among adults in South 
Africa, low baseline BMI was associated with poor immunological response one year 
after initiation of HAART.96 
All told, the preponderance of evidence points towards a deleterious effect of 
undernutrition on survival in both the absence and presence of ART, with far less known 
about how nutritional status influences CD4 levels. While studies to measure the clinical 
progression and immunological effects of HAART among children in resource-deprived 
areas are nonexistent, the impacts of nutritional status on survival have been examined in 
such a setting. However, it should be noted that these investigations, like the majority of 
observational studies to assess the immunological response to HAART, have focused 
only on treated subsets – the effects of differential nutritional status in the context of 
HAART have been quantified, but the effects of HAART in the context of differential 
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nutritional status have not. This is a subtle distinction, but quantifying how HAART 
works across degrees of nutritional status, in addition to the existing knowledge of how 
individuals with varying nutritional status progress during HAART, would substantively 
contribute to the debate on when to start HAART with regards to nutritional status. 
In its pediatric antiretroviral guidelines,105,157 the WHO suggests delaying 
HAART until severe undernutrition is stabilized but admits that this recommendation is 
based on expert opinion and not actual data. If studies indicate that HAART is less 
effective in the presence of undernutrition, this would support calls for adjuvant 
nutritional supplementation for HIV-infected children226,227 and perhaps even the delay of 
HAART in the presence of poor nutritional status, a path at odds with the conclusion of a 
recent study in untreated Zambian children that revealed substantial CD4 losses during 
successful nutritional rehabilitation.228 Such information could valuably inform policy, 
especially since a trial in severely malnourished children to compare immediate HAART 
without nutritional supplementation to immediate or delayed HAART plus nutritional 
supplementation is ethically untenable. The WHO105,157 and the Blantyre Working 
Group227 have stated that further research on the effectiveness of ART in severely 
undernourished children is urgently needed. 
The information presented in this section collectively informs hypotheses for 
future studies – it is speculated that children with greater undernutrition at HAART 
initiation would have an increased hazard of death, clinical progression, and not attaining 
immune recovery. While no studies have examined how baseline nutritional status 
influences the survival, clinical progression, and immunological effects of HAART, 
substantive knowledge of the consequences of undernutrition (e.g., deleterious survival 
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and immunological impacts) informs the hypotheses that lesser undernutrition would be 
associated with a greater reduction in the hazard of death and clinical progression by 
HAART, and that greater undernutrition would be associated with a reduced increase in 
CD4 percentage at all time points. If future studies reveal, for example, that HAART 
unequally affects progression across levels of undernutrition and that undernourished 
children have poorer post-HAART outcomes, they would not only encourage care and 
treatment programs to prioritize and provide nutritional supplementation. They would 
also offer essential empirical evidence that HAART initiation decisions should consider 
nutritional status, and support the expert opinion that HAART might best be delayed in 
the presence of undernutrition. 
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